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SUMMARY (English) 
Smoking is the leading cause of premature mortality and morbidity globally (WHO, 
2018). Within the Czech Republic (CR) tobacco consumption ranks among the 
highest in the world, and tobacco control measures rank among the poorest globally 
(Joossens and Raw, 2014; American Cancer Society, 2018). Smoking related chronic 
diseases and the loss of active part of life are an enormous and growing burden on the 
Czech system. There is urgency to invest in efforts that will control and decrease the 
demand for tobacco products (OECD, 2017). Experiences and lessons learned in 
tobacco control (TC) by other countries, such as Canada, may provide valuable 
insight to help guide Czech decision makers in identifying policy best buys moving 
forward.
The basic research carried out as part of this PhD project focuses specifically on a 
comparison of TC in Canada and the CR. It also includes: 1) a national cross-sectional 
survey of all organizations involved in TC to describe capacity and involvement in 
TC measures outlined by the WHO Framework Convention on Tobacco Control 
(FCTC) (Fraser et al. 2019); 2) a prospective cohort study which describes the results 
of intensive smoking cessation treatment offered by Centers for Tobacco Dependent 
(CTD) (Králiková et al. 2014); 3) a cross sectional survey of patients (N=203) in the 
national lung transplant program to describe the prevalence of smoking post lung 
transplantation and prior to inclusion on the transplant waiting list (Zmeškal et al. 
2015); and 4) a keyword search of clinical practice guidelines (N=91) from 20 
medical professional societies to determine whether tobacco dependence 
treatment recommendations were included (Zvolská et al. 2017).
Our findings provide evidence that many of the organizations involved in TC 
activities are under resourced, lack core chronic disease prevention skills and face 
many barriers to moving the tobacco control agenda forward (Fraser et al. 2019). 
CTD across the CR offer intensive treatment which was found to be highly effective 
(Králiková et al. 2014). Among patients who used pharmacotherapy as part of 
treatment, the 12-month abstinence rate was 43.4 % (N=2470) compared to 15.9 % 
(N=573) among those who did not (Králiková et al. 2014). CTD were underutilized 
and many physicians did not routinely refer patients. We also found that among those 
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who are critically ill, smoking resumption may be an under-recognized risk, 
particularly among patients with chronic obstructive pulmonary disease (COPD). We 
found that 15.1% (95% CI 0.078 to 0.269) of all lung transplant recipients had urinary 
cotinine levels corresponding to active smoking; and a further 3.8% (95% CI 0.007 to 
0.116) had borderline results.  Compared to patients with other 
diagnoses, patients with COPD were 35 times more likely to 
resume smoking post- transplantation (95% CI 1.92 to 637.37, p-value 0.016).  More 
rigorous screening, as well as support and treatment to stop smoking among critically 
ill patients are needed (Zmeškal et al, 2015). 
Further to this, clinical practice guidelines (CPG) do not adequately address tobacco 
use (Zvolská et al. 2017). Nearly one third of CPG (27.7%) related to cardiovascular 
and respiratory diseases, as well as cancer, made no mention of smoking. Only 13.8% 
of CPG included a section on tobacco dependence, referenced tobacco 
dependence treatment guidelines or mentioned specialized treatment centres where 
smokers can be referred. This represents a major gap in translation of research 
findings into clinical practice. 
Our findings provide empirical evidence that there are major gaps relating to 
treatment of tobacco dependence, as well as tobacco control more generally within the 
CR.  To change this should become a priority. 
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SUMMARY (Czech) 
Globálně je kouření vedoucí příčinou morbidity a předčasné mortality (WHO, 2018). 
ČR se spotřebou tabáku řadí na přední pozice ve světě, zatímco úroveň kontroly 
tabáku (KT) naopak patří celkově k nejnižším (Joossens and Raw, 2014; American 
Cancer Society, 2018). Chronická onemocnění v důsledku kouření a ztráta 
ekonomicky aktivních let v důsledku kouření jsou pro ČR významnou zátěží. 
Investovat do kontroly tabáku a snižovat tak poptávku po tabákových výrobcích by 
mělo být prioritou (OECD, 2017). Zkušenosti a znalosti na základě KT v jiných 
zemích, jako například v Kanadě, by mohly významně pomoci v rozhodování a 
pokroku správným směrem v KT v České republice volbou těch
nejvhodnějších a nejúčinnějších opatření.
Základní výzkum, který je součástí této dizertační práce, se zaměřuje specificky na
porovnání KT v Kanadě a ČR. Zahrnuje také: 1) národní průřezovou studii všech 
organizací zabývajících se kontrolou tabáku včetně popisu jejich kapacity a zapojení 
do aktivit KT podle doporučení Rámcové úmluvy o kontrole tabáku Světové 
zdravotnické organizace (FCTC) (Fraser et al. 2019); 2) prospektivní kohortovou 
studii, která popisuje výsledky intenzivní léčby závislosti na tabáku ve 
specializovaném Centru pro závislé na tabáku (CZT) (Králiková et al. 2014); 3) 
průřezovou studii mezi pacienty v národním programu transplantace plic (Tx plic, 
N=203), popisující prevalence kouření po Tx plic a před ní po zařazení na čekací 
listinu (Zmeškal et al. 2015); and 4) vyhledávání klíčových slov v doporučených 
postupech hlavních klinických oborů (N=91) dvaceti odborných společností s cílem 
posoudit, zda obsahují doporučení léčby závislosti na tabáku (Zvolská et al. 2017).
Naše výsledku ukazují, že mnohé organizace zabývající se KT jsou podfinancovány, 
nejsou vyškoleny v prevenci chronických nemocí a ve snaze o lepší úroveň KT se 
potýkají s mnohými překážkami (Fraser et al. 2019). CZT po celé ČR nabízejí 
intenzivní léčbu závislosti na tabáku, která je velmi účinná (Králiková et al. 2014): 
roční abstinence u pacientů užívajících farmakoterapii byla 43,4 % (N=2470) 
v porovnání s 15,9 % (N=573) bez farmakoterapie (Králiková et al. 2014). Tato 
centra však nejsou dostatečně využívána a pacienti tam nejsou rutinně doporučováni. 
Kouření je podceňovaným zdravotním rizikem i u kriticky nemocných, konkrétně u 
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pacientů s chronickou obstrukční plicní nemocí (CHOPN): v našem souboru (Tx plic) 
mělo 15,1% (95% CI 0,078 - 0,269) všech pacientů po Tx plic hladinu kotininu v 
moči odpovídající aktivnímu kouření a dalších 3,8 % (95% CI 0,007 – 0,116) hodnoty 
hraniční. V porovnání s pacienty s ostatními diagnózami byla pravděpodobnost 
kouření po Tx plic 35x vyšší u pacientů s CHOPN (95% CI 1,92 – 637,37, p= 
0,016). U kriticky nemocných je žádoucí pečlivý screening a podpora v nekuřáctví i 
nabídka léčby závislosti na tabáku (Zmeškal et al, 2015). 
Dále, doporučené postupy (DP) klinických oborů se adekvátně nezabývají užíváním 
tabáku (Zvolská et al. 2017). Téměř třetina DP (27,7%) v oborech spojených s 
kardiovaskulárními, respiračními či nádorovými nemocemi kouření vůbec nezmiňuje. 
Závislost na tabáku, odkaz na doporučení léčby závislosti na tabáku či CZT, kam 
mohou být doporučeni kuřáci, zmiňuje jen 13,8 % DP. To je významným 
nedostatkem v aplikaci výsledků výzkumů do klinické praxe. 
Z uvedených výsledků plyne empirický závěr, že v ČR jsou nejen mezery v oblasti 
léčby závislosti na tabáku, ale i v úrovni kontroly tabáku obecně.  Změna v této 
oblasti by měla být prioritou. 
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1.0 Introduction
Tobacco use is the leading cause of preventable death, disease and impoverishment 
globally (WHO, 2015). Within the Czech Republic, tobacco consumption ranks 
among the highest in the world, and tobacco control measures rank among the poorest 
globally (Joossens and Raw, 2014) (American Cancer Society, 2018). Smoking 
related illnesses claim the lives of about 14,000 people in the CR each year (Peto R, et 
al., 2015).  Smoking related chronic diseases are an enormous and growing burden on 
the Czech health care system. There is growing urgency to invest in efforts that will 
decrease the demand for tobacco (OECD, 2017).
  
Between 1985 and 2007-8 the prevalence of smoking among males decreased in the 
Czech population (from 49.2 % to 34.0 %), while the prevalence of smoking among 
women remained unchanged (Allender, et al., 2002) (Cifkova, et al., 2004). 
Undoubtedly, this decrease in tobacco consumption contributed to the massive decline 
in cardiovascular and stroke mortality in the CR (40% and 60% respectively) during 
this same time period (European Society of Hypertension, 2019). By 2011, the 
prevalence of tobacco use had declined but was still high compared to other 
developed western countries of the European Union (EU), about 29% (32.6% men, 
25% women) (Cifkova, 2006; Sovinová et al., 2012). 
 
While the public health system has traditionally played a central role in chronic 
disease prevention, it is critical that other sectors, as well as actors outside the public 
sector are involved in tobacco control (WHO, 2014). Tobacco use is a complex 
societal problem, influenced by an array of factors- many of which lie outside the 
influence of the health sector.  Tobacco control requires comprehensive and integrated 
action across sectors to improve coherence, effectiveness and efficiency of tobacco 
control policies (WHO, 2014, Christensen and Lægreid, 2006).
16
1.1 Tobacco Use in Canada and Czech Republic 
As the CR continues to strengthen tobacco control (TC) measures, experiences and 
lessons learned in other countries may provide valuable insight. Canada, in particular, 
has long been viewed as a leader in TC globally. In Canada scientists, non-
government organizations, community groups and other advocates have lobbied 
government for decades to adopt tougher TC legislation. Thanks to these efforts, since 
1965 the prevalence of smoking in Canada has dropped from nearly 50% to 15.1% 
(Reid et al, 2017).  In 2015, the prevalence of daily tobacco use among Canadian 
adults (age 15 years and older) was 12.7% of males and 8.5% of females. In contrast, 
smoking was considerably higher among Czech adults in the same age category, with 
21.8% of males and 14.8% of females using tobacco daily (American Cancer Society, 
2018). In 2013, daily use of smokeless tobacco products among Czech adults was 
1.7%, more than four times greater than that (0.4%) among Canadians (American 
Cancer Society, 2018 and 2020).
Among children age 10-14 years in the CR daily tobacco use was twice that of their 
Canadian counterparts in 2015 (American Cancer Society, 2018 and 2020). In 
Canada, 1.24% boys and 1.86% girls used tobacco daily, compared to 3.3% boys and 
4.5% of girls in the Czech Republic (American Cancer Society, 2018 and 2020).
While Canada has made significant progress in TC in recent years, smoking attributed 
death and disease continues to be an enormous problem with a high cost to society. 
Each year, tobacco use is responsible for 19.4% and 15.6% of all deaths in Canada, 
among males and females respectively (American Cancer Society, 2020). This being 
said, much of Canada’s success to date has largely been attributed to political will, 
community engagement and dedicated human and financial resources to move the 
country’s tobacco control agenda forward (Smoke Free Kings, 2013). Canada’s 
experiences offer a roadmap that may help guide other countries, such as the Czech 
Republic in strengthening their tobacco control measures and identifying policy best 
buys.  
17
1.2 Canada’s Tobacco Control Strategy 
In 2001, Nova Scotia one of Canada’s smallest provinces, released a landmark 
comprehensive tobacco control strategy that outlined a series of strategic directions 
aimed to reduce tobacco harms among Nova Scotians. In the 8-year period between 
2000 and 2008 the smoking rate dropped from 30% to 20% in Nova Scotia (Smoke 
Free Kings, 2013). During this same period youth smoking decreased by 50% and the 
percentage of children exposed to second hand smoke at home dropped from 30% to 
10% (Smoke Free Kings, 2013). In 2015, Nova Scotia became the first jurisdiction in 
the world to ban menthol and other flavored tobacco products; by 2017 this ban was 
nation wide (Canadian Cancer Society, 2020). Nova Scotia’s landmark strategy 
engaged partners across sectors and multiple levels of government. It was rooted in 
the shared understanding that tobacco use is a complex societal problem that requires 
diverse multi-sectorial action to achieve a shift in social norms to effectively decrease 
the prevalence of smoking (Smoke Free Kings, 2013).
In 2018, the Canadian government released a new Federal Tobacco Control Strategy 
and committed to reducing tobacco use nationally to less than 5% by 2035 
(Government of Canada, 2020). In order to achieve this ‘endgame’ target, the 
government committed $300 million dollars to address TC in the next 5 years alone 
(Government of Canada, 2020). Strategy funding will be used to help Canadians quit 
tobacco products, protect the health of youth and non-smokers from the dangers of 
tobacco use, work with indigenous populations, and to strengthen science, 
surveillance and partnerships (Government of Canada, 2020). Canada’s national 
tobacco strategy recognizes that tobacco use is not spread equally across the entire 
population (Government of Canada, 2020). The major challenge going forward will 
be to identify those interventions that have the greatest impact in decreasing the total 
number of smokers and address health and social inequalities associated with smoking 
(Chaiton and Callard, 2019).
1.3 Current Tobacco Control Policies 
  
TC action in Canada and the CR has been strategic and align with evidence based 
measured outlined by the WHO’s Framework Convention on Tobacco Control 
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(FCTC) (WHO, 2003). Both countries warn people about the dangers of tobacco use 
on products and have taken steps to reduce advertising. Since 2020, Canada has 
required that all tobacco products sold in retail shops to have plain standardize 
packaging. Branding with colours, graphics and logos on packages is prohibited 
(Canadian Cancer Society, 2020). Tobacco products are not displayed and advertising 
at point of sale is prohibited. In contrast, the Czech Republic still allows branding of 
tobacco products, point of sale advertising and product displays at point of sale 
(American Cancer Society, 2018). Both Canada and the CR use graphic health 
warnings to warn about the dangers of smoking, but the size of these warnings on 
packages differ by country. In 2012, new federal regulations in Canada came into 
effect increasing the size of health warnings to 75% of the front and back of cigarette 
packages and including a toll-free quit line number and web address in the warnings. 
While progress has been made in the CR, health warnings still fall below international 
best practice standards (plain package) and cover only 65% of the package surface 
area (American Cancer Society, 2018).
Smoking Bans and Advertising   
In 2004, Manitoba, New Brunswick, Northwest Territories and Nunavut were the first 
Canadian provinces/territories to adopt legislation for smoke-free restaurants and bars, 
all remaining provinces/territories followed shortly thereafter (Canadian Cancer 
Society, 2020). After years of debate, it was not until 2017 that the CR finally 
enforced a similar ban on smoking in restaurants and bars. Presently both countries 
have smoking bans in all health care and educational facilities, universities, and public 
transport (American Cancer Society, 2018 and 2020). However, smoking is still 
permitted in some indoor offices in both countries, and as of 2020 only Canada had 
funding dedicated to smoke free enforcement (American Cancer Society, 2018 and 
2020). 
Since 2008 it has been illegal in many parts of Canada to smoke in a car or other 
motor vehicle if anyone age 15 years or younger is inside (Canadian Cancer Society, 
2020). This smoke-free motor vehicle law went on to be implemented nationally and 
also includes vaping (Canadian Cancer Society, 2020). It is illegal in Canada to 
smoke or vape on the outdoor grounds of a community recreational facility and any 
19
public areas within 20 metres of its grounds (Ontario Ministry of Health, 2020). 
Canada has a total ban on the publicity of financial or other sponsorship or support by 
the tobacco industry of events, activities, and individuals (American Cancer Society, 
2020). Until recently publicity, sponsorship and/or support from the tobacco industry 
were still not completely banned in the CR (American Cancer Society, 2018). 
1.4 Economics of Tobacco Use 
The tobacco industry is a powerful entity that possesses enormous resources and 
market power globally. In 2016, the combined revenue of six largest tobacco 
companies in the world was 90% greater than the Czech Republics Gross National 
Income (American Cancer Society, 2018). Comparatively, this sum represented about 
23% of Canada’s Gross National Income (American Cancer Society, 2020). Countries 
such as Canada, which have larger economies and population, have the opportunity to 
help smaller allies by leading the way in the fight against industry globally (American 
Cancer Society, 2020).
 According to the WHO, increasing the price of tobacco products through 
aggressive tax measures is one of the most effective ways to decrease tobacco 
consumption and increase government revenues (WHO, 2008). Depending on the 
situation in a given country the ideal tax level may be a combination of two forms 
of excise tax, specific taxes and ad valorem. Specific taxes are a fixed amount per 
unit of tobacco (e.g. $1 per 20 cigarettes), whereas, ad valorem taxes add a 
percentage to the price (e.g. a tax of 60% of pre-tax price). The tax benchmark set 
by the WHO recommends at least 70% excise tax share in final consumer price. 
Currently both countries fall short of this benchmark, with excise tax set at 58.06% 
and 55.35% in CR and Canada, respectively (American Cancer Society, 2018 and 
2020). 
Taxation of sale of tobacco products represents a lucrative source of income for 
governments, but comes at a high societal cost. Numerous studies have documented 
the economic impact of smoking in terms of both direct health care costs and indirect 
expenditures due to lost productivity and early onset illness and mortality (Goodchild 
et al. 2017). In 2012, smoking related diseases accounted for 5.7% of health 
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expenditures globally (Goodchild et al. 2017). The total economic burden of smoking 
was shown to be 1.8% of our global gross domestic product (GDP) (Goodchild et al. 
2017). In the most recent data published by the American Cancer Society in the 
Global Tobacco Atlas it was estimated that the annual economic impact of smoking in 
the Czech Republic was near 103265 million koruna, and 32,018 million dollars in 
Canada (2018 and 2020). The seemingly unlimited resources of the tobacco industry, 
along with wide spread corruption and manipulation by industry have made this 
public health crisis difficult for countries to address. 
In 2012, Shirane et al. uncovered clear evidence of ongoing manipulation of the 
tobacco industry over tobacco advertising and excise policies in the CR (Shirane et al. 
2012). These findings helped illuminate why the country has had such a weak record 
of TC. The authors also highlighted that there is significant opportunity for the CR to 
create large increases in tobacco tax (rather than small incremental increases) that will 
help decrease the demand (Shirane et al. 2012). The only question that remains is 
whether or not there is political will to do so. 
1.5 Tobacco Dependence and Treatment 
Tobacco dependence is a chronic disease characterized by relapse and remission, 
which can be reported according to the International Classification of Diseases 10 
(ICD-10) code F17 (Hughes et al, 2004) (International Classification of Diseases and 
Related Health Problems, 2011). Among smokers who stop without help, or using 
methods with placebo effect, the long-term success rate is about 5% (Fiore et al. 
2008). The World Health Organization (WHO) recommends that all physicians 
should provide a brief intervention for tobacco use to a patient at each clinical contact. 
With brief intervention the success rate is 5‒10% (Fiore et al, 2008). A brief 
intervention consists of 5 points known as the “5 A’s”. The intervention involves 
asking the patient about tobacco use, advising the patient to quit, assessing readiness 
to quit, assisting the patient in quitting, and arranging for follow up (Fiore et al, 
2008). If a patient is unable to stop smoking, they should be referred to receive more 
intensive specialized treatment. Within the CR, specialized treatment for tobacco 
dependence (psychobehavioural therapy and pharmacotherapy) is available and 
21
delivered by clinicians at Centres for Tobacco-Dependent (CTD) (Zvolská and 
Králíková, 2017).  
In Canada, smoking cessation supports are integrated into the provincial health care 
system. Free of charge, one-on-one or group cessation treatment and support are 
available to all smokers by phone, Internet or in person (Province of Nova Scotia, 
2020). Nicotine replacement therapy (NRT) products or prescription smoking 
cessation drugs are either fully or partially reimbursed under all health insurance plans 
in Canada (Johnson and Johnson, 2018). 
 
2.0 Tobacco dependence and treatment in the Czech Republic. 
Since 2005, a network of Centres for Tobacco Dependent (CTD) has systematically 
grown in the CR mostly within large hospitals. Centres were based on the model of 
the Nicotine Dependence Centre at Mayo Clinic, Rochester, Minnesota, USA. 
Presently there are 36 CTDs across the CR (with the population of 10.49 million) 
(Zvolská and Králíková, 2017).  The first Referential Center for Tobacco-Dependent 
was established in Prague at the General University Hospital in 2005. Since that time, 
the centre has treated about 500 new patients per year; representing approximately 
60% of all patients treated by CTDs in the CR (Zvolská and Králíková, 2017). Among 
patients who receive intensive treatment at CTDs, the success rate is over 30% after 
one year (Králíková, et al 2013; WHO, 2014).
2.1 Society for the treatment of tobacco dependence
The Society for the Treatment of Tobacco Dependence (Společnost pro léčbu 
závislosti na tabáku, SLZT) provides on-going support, information and resources to 
medical professionals on evidence based tobacco dependence treatment measures 
within the CR. Doctors, nurses, pharmacists, and other health care practitioners are 
encouraged to provide brief interventions, just 2 of the 5 A´s and R – the Ask, Advise, 
and Refer approach to treat patients who use tobacco. Unfortunately, treatment is still 
not widely accessible and many people within the CR have to travel long distances to 
receive treatment for nicotine dependence (Zvolská and Králíková, 2017)
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2.2 Pharmacotherapy 
Tobacco dependence medications are available within the CR, with the exception of 
nasal inhalers and lozenges. However, health insurance companies do not cover 
smoking cessation medications. This cost is a barrier for some smokers to stop 
(Zvolská and Králíková 2017). A 3-month supply of these medications costs about the 
same as a 3-month supply of cigarettes, based on a consumption of 20 cigarettes per 
day. There is evidence that patients of higher socio-economic status (SES) may be 
more aware of the health risks of smoking and may seek treatment for tobacco 
dependence more often than their low SES counterparts (Steptoe and Marmot, 2004). 
Therefore investment in tobacco control measures beyond cessation treatment, such as 
taxation, bans on advertising, health warnings on packages and creation of smoke free 
environments are important strategies recommended by the WHO Framework 
Convention on Tobacco Control (FCTC). These strategies address the determinants of 
health at a primordial level (WHO, 2003). 
2.3 Clinical practice guidelines
Within the CR, most physicians partially use brief intervention with patients who 
smoke, but the 5A’s are still not part of standard clinical practice. In 2011, Králíková 
et al. reported that eighty percent of Czech physicians ask about tobacco use and 
advise patients to quit. However, subsequent steps of the brief intervention were not 
delivered including; assess readiness to quit, assist and arrange follow up (Králíková 
et al., 2015). 
Clinical practice guidelines (CPG) are systematically developed statements to assist 
practitioners and patients in making appropriate decisions about health care for 
specific clinical circumstances (Field and Lohr, 1992). These guidelines facilitate the 
transfer of evidence into clinical practice. The WHO recommends a systematic 
approach for incorporating brief tobacco interventions into primary health care 
services (WHO, 2014). 
Clinicians of all disciplines should be educated on and follow CPG relating to 
evidence based treatment of nicotine dependence and tobacco related co-morbidities. 
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Despite the clinical significance of smoking, few of the approximately 120 medical 
professional societies in the CR adequately addressed tobacco dependence and 
treatment in their CPG documents (Zvolská et al. 2017). According to Zvolská et al. 
CPG documents from selected medical professional societies in the Czech Republic 
did not adequately address the importance of smoking cessation (2017). Smoking 
cessation should not be viewed as a mere lifestyle change, but rather imperative to 
good health and a necessary part of treatment for many diseases. CPG are an 
important source of evidence-based information for clinicians. CPG should provide 
up to date information on tobacco dependence, treatment and highlight the importance 
of using brief intervention with patients who smoke at each clinical contact. 
2.4 Cardiovascular disease (CVD) and smoking 
Within developed countries cardiovascular diseases (CVD) rank among the main 
causes of death (Adámková, 2010). This trend is also true in the CR, where CVD 
constitutes one of the main causes of death and hospitalization (Zdrav. ročenka, 
2016). Smoking is major preventable risk factors of CVD morbidity and mortality, 
together with high blood pressure, diabetes and hypercholesterolemia (Gikas et al. 
2016). CVD are the most common cause of death among smokers. Within the EU, 
CVD is responsible for about 42 % of all deaths each year. In the Czech Republic, 
smoking is responsible for about 15 % of all CVD deaths, this accounts for more 
deaths each year than lung cancer, the most common form of cancer caused by 
smoking (Peto et al. 2015).
Since the mid 1980s, CVD mortality has declined in the CR (Zemřelí, 2011). Between 
2003-2009, the standardized mortality among men in the CR decreased by 23.3%. 
During this same time period, CVD mortality decreased a similar percentage (23%) 
among women, from 384.4 to 296.2 per 100 thousand inhabitants. Compared to other 
EU countries, within the CR the incidence of CVD morality at that time was higher 
(the standardized mortality in men 289.9/100,000 and women 190.3/100,000 in EU in 
2009) (Cayotte and Buchow, 2009; Institute of Health Information and Statistics of 
the Czech Republic, 2009).  
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Since the mid 1980s, mean cholesterolaemia, as well as systolic and diastolic blood 
pressure have significantly decreased. As a result, CVD mortality, particularly due to 
stroke has declined (Cifkova, et al. 2010). In a random population sample of the CR 
over the period from 1997-98 to 2006-09, the prevalence of hypertension rose but 
treatment and control of hypertension and dyslipidemia improved (Jozifova et al. 
2011). 
Among patients in Europe with establish coronary disease, the prevalence of smoking 
is very high (21 %) (Sumanen et al, 2004; Scholte, 2006). More than half of coronary 
patients who were smoking at the time of their event were still smoking one year later, 
according data from the EUROASPIRE survey (Kotseva et al. 2009). 
For patients with acute coronary syndrome, there is a system of twenty-two 
cardiocenters nationally and the CR is recognized for its’ excellence in caring for 
these patients. Control of cholesterol and hypertension within the CR are among the 
best in Europe, which is a major advance in terms of population health. While 
smoking rates have continued to decrease since the late 1990s (Sovinova et al. 2012) 
(American Cancer Society, 2018) the Czech government continues to invest in 
initiatives that focus on public education and awareness of CVD risk factors (Tóthová 
et al., 2018) rather than implementing evidence based policies that have been shown 
to have the biggest return on investment (WHO, 2003).
2.5 Continued smoking among the critically ill
Among tobacco users who suffer from chronic health conditions, nicotine dependence 
is a major barrier to cessation. Despite the severity of their illness and the knowledge 
that quitting would have important long-term benefits, many tobacco users are unable 
to stop smoking (Woodward M and Tunstall-Pedoe 1992; Archbold et al. 1995; van 
Berkel et al. 1999). This may not be due to the lack of motivation to stop smoking, 
but rather a matter of dependence for these patients (West, 2004). 
Among patients with end-stage lung disease, for many lung transplantation (Tx) 
remains the best treatment option. However, the demand for lung transplantation 
greatly exceeds availability, yet developing rigorous selection criteria and methods to 
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identify suitable transplant recipients continues to present unique challenges. 
Furthermore, despite lung Tx candidates’ reliable self-reported disclosure of active 
smoking, it is unlikely that their survival may depend on inclusion on the Tx waiting 
list (WL). Due to the limited number of suitable donors and the high demand for Tx, it 
is important that centres are able to detect patients who deceptively report smoking 
behaviour in order to select patients who will have the best outcomes long term. The 
implementation of routine screening protocols may help centers identify those 
candidates who are likely to have the best outcomes post transplantation. This is 
discussed further in chapter 6.
3.0 Framework Convention on Tobacco Control (FCTC)
The WHO Framework Convention on Tobacco Control (FCTC) and its guidelines 
provide the foundation for countries to implement and manage tobacco control 
(WHO, 2003). By 2025, the World Health Organization (WHO) and its Member 
States have set a voluntary global target of a 30% relative reduction in the prevalence 
of current tobacco use (WHO, 2013). Strengthening WHO FCTC implementation 
through the Health 2020 policy framework and the roadmap of actions to strengthen 
implementation will ensure that the Czech Republic is not left behind.
The FCTC outlines six evidence-based MPOWER measures that are best buy 
interventions, proven to reduce the demand for tobacco. The MPOWER measures are: 
Monitor tobacco use and prevention policies; Protect people from tobacco smoke; 
Offer help to quit tobacco use; Warn about the dangers of tobacco; Enforce bans on 
tobacco advertising, promotion and sponsorship; and Raise taxes on tobacco. Each 
has been shown to reduce the prevalence of tobacco smoking, but the effect depends 
on their level of implementation and the implementation of other tobacco-control 
policies (Levy et al., 200; United States Department of Health and Human Services, 
2014). To meet WHO global targets and support national tobacco control efforts, 
policymakers must know the individual and combined effects of MPOWER measures 
(WHO, 2013). In addition to this, countries must coordinate TC efforts across sectors 
and ensure groups and organizations have the necessary resources, skills, leadership 
and supports to work effectively. 
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3.1 Organizational capacity for tobacco control
Within the Czech Republic, little is known about i) what types of organizations are 
involved in tobacco control; ii) what structures, supports, resources and skills these 
organizations possess to work on tobacco control or; iii) their level of involvement in 
tobacco control related activities. In order to better understand current tobacco control 
efforts in the Czech Republic, we conducted a capacity assessment with all 
organizations activity involved in tobacco control at a national level in the 3 years 
previous to data collection. This study is described in section 4.0. 
3.2 What is a capacity assessment?
A capacity assessment is a way to measure the strengths, opportunities, barriers and 
obstacles for the implementation of evidence based tobacco control measures. The 
purpose of conducting a capacity assessment is to assess the status and present 
development efforts of key tobacco control policies, leadership and commitment to 
tobacco control as well as partnerships and networks, human and financial resources, 
as well as infrastructure. The goal of building national capacity is a comprehensive 
and sustainable national strategy for multi-sectoral tobacco control programs and 
policies.
3.3 What is the end product of a capacity assessment?
The end product of a capacity assessment is a set of recommendations with potential 
actions to guide government and civil society at any stage in the process of 
developing, implementing or evaluating their approach to tobacco control.  A capacity 
assessment can provide government with a better understanding of the strengths and 
limitations of current tobacco control efforts. It can also help inform specific 
recommendations on how best to increase political commitment and how to reorient 
and optimize policy interventions. It can also provide evidence to inform the 
development of national tobacco control strategy. 
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3.4 Aim and objectives 
To better understand the strengths and limitations of current tobacco control efforts 
within the CR we conducted a cross sectional survey of all organizations actively 
involved in tobacco control at a national level in the 3 years prior to data collection. 
We focused specifically on organizations involved in chronic disease prevention 
activities that address tobacco use. 
Our aims were
 to describe key determinants of organizational capacity including; 
organizational supports, partnerships, resources, leadership, and skills for 
tobacco control. 
 to describe organizations‘ level of involvement across settings, strategies used, 
and level of involvement in MPOWER measures. 
Our findings provide data, which identifies strengths and gaps in organizational 
capacity, and provide an evidence base to help guide decision makers to identify 
strategic priorities. 
3.5 Original contribution to knowledge 
 To our knowledge, this is the first national survey of organizational capacity 
and level of involvement in tobacco control related activities among 
organizations in the Czech Republic.
 Until now, little was known about the capacity of these organizations to 
deliver effective chronic disease prevention programs that address tobacco 
use. 
 Our findings provide empirical evidence to local decision makers to help 
inform strategic priorities and decrease the demand for tobacco in the Czech 
Republic. 
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4.0 FCTC implementation: The role of state or non-government organizations? 
An example of Czech Republic 
Tobacco use is the leading cause of preventable death, disease and impoverishment 
globally (WHO, 2015). According to the World Health Organization (WHO), Europe 
has the highest prevalence of tobacco smoking among adults (28%) and among the 
highest prevalence of tobacco use by adolescents (WHO, 2019). In the Czech 
Republic, tobacco consumption ranks about 25% in the population age 15-65 years, 
and tobacco control (TC) measures rank among the poorest globally (Váňová et al. 
2018; Joossens and Raw, 2014; American Cancer Society, 2018). Among all tobacco 
related chronic diseases, smoking is responsible for one in every six deaths in the 
Czech Republic (Peto R, et al. 2015). The burden of tobacco use on the Czech health 
care system and other tobacco-related costs call for growing urgency to invest in 
evidence based measures that will decrease the demand for tobacco (OECD, 2017).  
Tobacco use is a complex societal problem, influenced by an array of factors- many 
of which lie outside the influence of the health sector.  TC requires comprehensive 
and integrated action across sectors to improve coherence, effectiveness and 
efficiency of policies (WHO, 2014; Christensen and Lægreid, 2006).  The WHO 
Framework Convention on Tobacco Control (FCTC) and its guidelines provide the 
foundation for countries to implement and manage tobacco control (WHO, 2003). The 
FCTC outlines six evidence-based measures that are best buy interventions, proven to 
reduce the demand for tobacco (WHO, 2008). These measures are referred to 
collectively by the acronym MPOWER which stands for; monitor tobacco use and 
prevention policies, protect people from tobacco smoke, offer help to quit tobacco 
use, warn about the dangers of tobacco, enforce bans on tobacco advertising, 
promotion and sponsorship, and raise taxes on tobacco (WHO, 2008). 
In order for organizations to work effectively on TC related activities outlined by the 
FCTC, they must have the capacity to do so, in terms of resources, skills, leadership 
and supports. Within the Czech Republic, little is known about i) what types of 
organizations are involved in tobacco control; ii) the capacity these organizations may 
have in terms of structures, supports, resources and skills to work on TC related 
activities or; iii) their level of involvement in evidenced based TC activities. 
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Given the Czech Republic’s history of weak TC, our aim was to conduct a capacity 
assessment to better understand the strengths and limitations of current TC efforts as 
they relate to the FCTC (Joossens and Raw, 2014; WHO 2008). We conducted a cross 
sectional survey of all known organizations (N=20) involved in activities that address 
tobacco use. Our findings describe key determinants of organizational capacity 
including organizational supports, partnerships, resources, leadership, and CDP skills 
to carry out TC activities. We also examined organizations level of involvement 
across settings, strategies used, and their level of involvement in MPOWER measures. 
Our findings provide data, which identifies strengths and gaps in organizational 
capacity, and provide an evidence base to help guide decision makers to identify 
strategic priorities. To our knowledge, this is the first national survey of 




Between June and November 2017, cross-sectional data were collected in a survey of 
all organizations in the CR engaged in primary or secondary prevention activities 
relating to tobacco control at a national level in the last 3 years. Organizations were 
first identified by local tobacco control experts, and then through an exhaustive 
Internet search using purposive sampling. Organizations included; government 
ministries, offices and departments, public health organizations clinics, centers and 
commissions (herein referred to collectively as government organizations (GOV), 
non-government and non-profit organizations, alliances, networks, professional 
associations and societies, and health agencies (herein referred to collectively as non-
government organizations (NGOs). 
Prior to data collection, key informants with an in-depth knowledge of tobacco 
control in the CR validated the final list of organizations to be included in the study. 
A total of 20 organizations fit our inclusion criteria. This represented a complete 
census of all known organizations engaged in primary or secondary prevention of 
tobacco use in the CR at a national level, in the three years prior to data collection. 
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Organizations that operated at a regional or community level only were excluded, as 
were primary care facilities such as hospitals that focus mainly on tertiary prevention.
Study Variables 
In this study, organizational capacity was conceptualized to include leadership, 
supports, skills, partnerships and resources. Tobacco related activities were defined as 
any programs, policies, strategies, initiatives, or interventions that focus on reducing 
the demand for tobacco. Our survey tool was developed based on a comprehensive 
review of peer-reviewed literature and published reports of organizational capacity for 
chronic disease prevention and healthy lifestyle promotion (Smith et al. 2001; 
MacLean et al. 2001; Taylor et al. 1998; Joffres et al. 2004). Survey questions were 
drawn from a psychometrically sound scale developed by Hanusaik et al. (2007) to 
measure determinants of organizational capacity for chronic disease prevention, and 
adapted to focus specifically tobacco control. Four internationally recognized tobacco 
control experts helped established face validity of the questionnaire. The final 
working version of the survey was pilot tested with public health practitioners 
working in tobacco control in three district health authorities in Nova Scotia, Canada. 
The final version of the questionnaire consisted of 25 questions. The questionnaire 
gathered information about; organizational characteristics (that is, structural 
determinants of capacity); organizational supports of capacity; leadership, skills; 
resources; level of involvement in MPOWER measures and across settings; 
partnerships; facilitators and barriers to involvement in tobacco control related 
activities. Most response sets were five point Likert scales, with level of agreement 
response formats ranging from ‘‘1’’ (very low/ strongly disagree) to ‘‘5’’ (very 
high/strongly agree). 
A certified Czech translator translated the questionnaire from English to Czech. 
Researchers at the Center for Tobacco-Dependent of the Third Medical Department – 
Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles 
University and the General University Hospital in Prague, reviewed the questionnaire 
to ensure cross-cultural adaptation of all questions. 
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Organizations were initially contacted by email to solicit their participation in the 
study. A Czech-speaking interviewer followed up with each organization by phone or 
email, to confirm their participate and to set a date for data collection. One key 
informant per organization completed the survey. The survey respondent was 
identified by the head of the organization as most knowledgeable about tobacco 
control related activities within the organization. One survey was completed by each 
organization, with the exception of two organizations that worked closely on tobacco 
related activities and requested to complete one survey together. These two 
organizations were counted as a single organization in the analysis. Any incomplete 
data or inconsistencies were resolved with a follow up telephone call or e-mails. 
Statistical Analyses 
Since this study reports data collected in all organizations involved in tobacco control 
prevention at a national level (not a sample), significance testing was not relevant. 
Comparisons of means for continuous variables and frequencies for categorical 
variables were made between groups of organizations. Data analyses were conducted 
using IBM SPSS Statistics software, version 25. 
Ethics Approval 
The study received ethics approval from the ethics committee of the General 
University Hospital in Prague (study no. 39/16 S-IV). The head of each organization, 
as well as the survey respondent, provided written consent to participate in the study. 
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RESULTS
A total of 20 organizations met the inclusion criteria for the study. These 
organizations represented a complete census of all known organizations actively 
engaged in tobacco control from a chronic disease prevention perspective, at a 
national level in the CR in the three years prior to data collection. All organizations 
that met the inclusion criteria were invited to participate in the study. A total of 
fourteen organizations agreed to take part. 
Organizational structure and commitment 
Our final census included a total of 14 organizations, which included GOV (n=7) and 
NGO (n=7) organizations (Table 1). GOV organizations employed a median of 651 
full time employees, with a median of 10 individuals per organization involved in 
tobacco control in some capacity. Only two GOV organizations had full time 
equivalents (FTEs) dedicated to working on tobacco control, but the majority had 
none. The majority of NGO, had no full time employees, and operated using a 
membership model or relied on volunteers. NGO had a median of four individuals per 
organization working specifically on tobacco control, but no FTEs. The majority of 
both GOV and NGO organizations served the general public. About one third of all 
organizations served specific sub-populations such as, health care professionals, 
individuals with mental illness, and those with substance abuse problems. Overall 
organizations rated their level of involvement in tobacco control related activities as 
‘high’. TC related activities were rated as a ‘high’ or ‘very high’ priority for all, but 
one, organization. 
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Table 1. Characteristics of organizations involved in tobacco control in the Czech 
Republic, according to type of organization (Fraser et al., 2019). 
 








Number of FTEs at 
organization level b
2 (0-5000) 651 (23-5000) 0 (0-2)
Number of individuals 
working on TC at organization 
level c
7.5 (0-25) 10 (0-25) 4 (1-12)
Number of FTEs working on 
TC at organization level
0 (0-5) 0 (0-5) 0
Populations served by organization, %
General Population 71.4 71.4 71.4
Subpopulation d 28.6 28.6 28.6
Level of involvement in TC, 
mean (SD)e
4.0 (1.1) 3.7 (1.4) 4.3 (0.7)
TC’s level of priority for the 
organization, mean (SD)e
4.5 (0.7) 4.3 (0.9) 4.7 (0.5)
a: GOV= government ministries, offices and departments, public health organizations 
clinics, centers and commissions, NGO = non-government and non-profit 
organizations, alliances, networks, professional associations and societies, and health 
agencies 
b: FTEs = Full-time equivalents 
c: TC = Tobacco control 
d: Subpopulation= health care professionals, individuals with mental illness, or those 
with substance abuse problems.
e: Scored on a five-point Likert scale: 1 = very low; 2 = low; 3 = moderate; 4 = high; 
5 = very high.
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Organizational Supports 
Organizational capacity for tobacco control was conceptualized to include leadership, 
supports, skills, partnerships and resources (Table 2). Among the indicators for 
internal organizational supports, strategic priorities, leadership, managerial support, 
and professional development opportunities were rated relatively high. Adequate 
number of staff dedicated to working on TC activities was rated lower. Two thirds of 
organizations reported that they did not have an adequate number of staff working on 
TC activities to achieve their objectives. Fifty percent of organizations reported a low 
level of confidence in their staff’s knowledge and skills to work effectively on 
tobacco control-related issues. In terms of access to necessary equipment and tools 
(e.g. software, computers, literature, etc.), this was not reported as a major barrier, but 
NGO tended to rate this lower than GOV.
Partnerships
 
Partnerships are an indicator of external support for TC activities (Table 2). More than 
half of all organization had formed partnerships of some kind to work on TC related 
activities. Although, NGO tended to form more partnerships than GOV, partnership 
effectiveness was rated slightly lower. Formation of cross sector partnerships was 
rated very low by all organizations. 
Financial resources 
The majority of organizations rated their funding to support TC activities as ‘less than 
adequate’ or ‘much less than adequate’. Funding stability was rated lower by NGO 
than GOV. Availability of external sources of funding to support tobacco control 
related activities was rated low by all organizations. 
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Table 2. Levels of determinants (organizational supports, partnerships, financial 
resources) of organizational capacity for TC related activities in CR according to type 








Organizational supports to guide TC activities, mean (SD)a
Strategic priorities 3.9 (1.1) 3.9 (1.2) 4.0 (0.9)
Leadership 4.0 (0.9) 4.0 (1.1) 4.0 (0.8)
Managerial 4.1 (0.6) 4.3 (0.5) 4.0 (0.8)
Professional development opportunities 3.9 (0.7) 4.1 (0.6) 3.7 (0.7)
Adequate number of staff 2.4 (1.2) 2.7 (1.3) 2.0 (0.9)
Specialized knowledge and skills 3.6 (0.6) 3.7 (0.7) 3.4 (0.5)
Equipment and tools 3.4 (0.9) 4.0 (0.8) 2.9 (0.6)
Partnerships
% Organizations that had formed 
partnerships, mean
64.3 57.1 71.4
Partnership effectiveness [mean, (SD)] a 3.5 (1.0) 3.7 (0.9) 3.4 (1.0)
Partnerships formed across sectors [mean, 
(SD)] a
2.9 (1.1) 3.0 (1.2) 2.9 (1.0)
Financial Resources
Funding adequacy, mean (SD) b 1.8 (0.7) 2.0 (0.5) 1.5 (0.8)
Funding stability, mean (SD) c 2.5 (1.3) 3.1 (1.2) 1.6 (0.8)
Availability of external funding sources, 
mean (SD) a
2.1 (1.3) 2.3 (1.6) 1.8 (0.9)
a: Scored on a five–point Likert scale: 1 = totally or strongly disagree; 2 = disagree; 
3= neither agree nor disagree; 4 = agree; 5 = totally or strongly agree. 
b: Scored on a five-point Likert scale: 1 = much less than adequate; 2 = less than 
adequate; 3 = neutral; 4 = adequate; 5 = more than adequate. 
c: Scored on a five-point Likert scale: 1 = very unstable; 2 = somewhat unstable; 3 = 
stable; 4 = somewhat stable; 5 = very stable. 
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Core Chronic Disease Prevention (CDP) skills 
Organizational capacity, as it relates to core chronic disease prevention (CDP) skills, 
focused on tobacco control are presented in Table 3. CDP practice skills including, 
assessment, identifying relevant practices, developing and implementing initiatives 
were rated more favourably than skills to evaluate these activities. Only half of all 
organizations reported confidence in their skills to evaluate the impact of their TC 
work. 
Tobacco control efforts in specific settings
Among all organizations, involvement in tobacco control activities was highest in 
government settings, followed by health care settings. NGOs reported greater 
involvement in these settings, compared to GOV organizations. Few organizations 
were involved in tobacco control activities in workplaces or schools, with the lowest 
level of involvement in the community at large (Table 4). 
Intervention strategies used 
Overall, organizations were more involved in individual-level, rather than population-
level, chronic disease prevention strategies to address tobacco use (Table 4). Among 
individual-level strategies, organizations reported the highest level of involvement in 
activities that focused on public education to raise awareness. In contrast, less than 
half of all organizations were ‘very involved’ in population-level strategies, such as 
policy development, advocacy and creation of healthy environments, to address 
tobacco use. 
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Table 3. Skill level for core chronic disease prevention (CDP) practices to address 
tobacco use, levels of involvement in specific settings, and intervention strategies 








Core CDP practice skills specific to tobacco control activities, mean (SD) a
Assessment 3.8 (1.4) 4.1 (1.4) 3.2 (1.3)
Identifying relevant practices 3.9 (1.3) 3.3 (1.6) 4.4 (0.5)
Developing action plans 4.1 (1.1) 4.0 (1.4) 4.2 (0.7)
Implementation of activities 4.2 (1.1) 4.0 (1.4) 4.4 (0.5)
Evaluation 3.1 (1.4) 3.2 (1.3) 3.0 (1.5)
Level of involvement in specific settings, mean (SD) b
Schools 2.1 (1.3) 2.6 (1.3) 1.7 (1.2)
Workplaces 2.6 (1.4) 2.9 (1.6) 2.4 (1.3)
Health care 3.3 (1.4) 3.1 (1.6) 3.4 (1.2)
Community at large 2.1 (1.0) 2.1 (1.1) 2.1 (0.8)
Government settings 3.5 (1.5) 3.1 (1.5) 3.9 (1.4)
Level of involvement in intervention strategies targeting individual level, mean 
(SD) c
Public education 2.7 (0.6) 2.6 (0.7) 2.9 (0.3)
Programs to build skills at 
individual level
2.3 (0.8) 2.3 (0.9) 2.3 (0.7)
Service provider skill building 2.3 (0.8) 2.2 (0.9) 2.4 (0.7)
Clinical interventions and 
treatment of individuals
2.3 (0.8) 2.2 (1.0) 2.3 (0.7)
Level of involvement in intervention strategies targeting population level, mean 
(SD) c
Public policy change and 
advocacy
2.4 (0.8) 2.5 (0.8) 2.2 (0.7)
Creating healthy environments 2.4 (0.6) 2.4 (0.7) 2.4 (0.5)
a: Scored on a 5-point Likert scale: 1 = poor; 2 = fair; 3 = moderate; 4 = good; 5 = 
very good. Response categories “not our role” and “don’t know” were also included 
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as options. In these cases organizations were excluded from the calculated mean. b: 
Scored on a 5-point Likert scale: 1 =very low; 2 = low; 3 = moderate; 4 = high; 5 = 
very high. Response categories “don’t know” and “not involved” were also options. In 
these cases, the response was classified as 1= very low.  c: Scored on a 3-point scale: 
1 = not at all involved; 2 = somewhat involved; 3= Very involved. “Don’t know” was 
also included as a response category and in these cases the organization was excluded 
from the calculated mean. 
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Level of involvement in MPOWER measures 
Level of involvement in MPOWER measures was highest for activities that focused 
on creation of smoke-free workplaces and public places, followed by health 
information and warnings on packages, and monitoring of tobacco use. Half of all 
organizations reported that they were ‘very involved’ in activities that focused on 
helping smokers to quit. Organizations reported the lowest level of involvement in 
MPOWER measures that focused on raising taxes, enforcing bans on tobacco 
advertising, promotion and sponsorship, as sales to minors. 
Barriers faced by organizations 
Organizations reported a range of barriers in working on tobacco control related 
activities (Table 4). Insufficient funding, inadequate number of staff dedicated to 
working specifically on TC, lack of political will or competing priorities, and strong 
interference from the tobacco industry were all reported as major barriers. 
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Table 4. Level of involvement in MPOWER measures and barriers faced, according 







Level of involvement in MPOWER measures, mean (SD)a
Raise taxes on tobacco 2.0 (0.8) 2.0 (0.8) 2.0 (0.8)
Smoke-free workplaces and public places 2.7 (0.6) 2.6 (0.7) 2.9 (0.3)
Health information and warnings on tobacco 
packages
2.4 (0.8) 2.6 (0.7) 2.3 (0.9)
Enforce bans on tobacco advertising, 
promotion and sponsorship
2.1 (0.8) 2.2 (0.9) 2.0 (0.8)
Monitor tobacco use 2.4 (0.9) 2.7 (0.7) 2.0 (0.9)
Offering smokers help to quit tobacco use 2.2 (0.9) 2.3 (0.9) 2.1 (0.8)
Sales to minors 1.8 (0.8) 2.3 (0.7) 1.3 (0.5)
Barriers (% organizations)
Insufficient funding 57.1 57.1 57.1
Insufficient number of staff 57.1 71.4 42.9
Lack of political will or competing priorities 42.9 57.1 28.6
Tobacco industry interference 28.6 28.6 28.6
a: Scored on a 3-point Likert scale 1=not at all involved, 2=somewhat involved, 
3=very involved. “I don’t know” was also included as a response option; in these 
cases the response was excluded from the calculated mean. 
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DISCUSSION
To our knowledge, this is the first national survey of organizational capacity for 
tobacco control, and level of involvement in MPOWER measures among 
organizations in the Czech Republic. Our findings show that despite the high 
economic costs of tobacco use, few organizations are actively involved in chronic 
disease prevention activities that address tobacco use. Organization’s tobacco control 
activities are under-funded and most do not have enough people working on tobacco 
control to achieve their organizations objective. Further to this, our findings provide 
evidence that Czech organizations are highly involved in intervention strategies that 
focus too far downstream to have any real impact on population health outcomes. 
In terms of organizational supports, most organizations reported that they had 
strategic priorities and good leadership to guide their tobacco control related work. 
Professional development opportunities were available, but less so to NGOs. Less 
than one third of organizations had a sufficient number of staff dedicated to working 
on tobacco control related activities, and many did not have the proper equipment or 
tools (e.g. software, computers, literature, etc.) to work effectively. NGOs reported a 
greater disadvantage in these areas, compared to GOV organizations. Our findings 
show that most organizations did not have a sufficient number of human resources 
dedicated to working on tobacco control to achieve their objectives. In addition to 
developing a critical mass of professionals dedicated to working on tobacco control, 
there is also a need to invest in helping these professionals to develop the specialized 
skills, knowledge, and tools to support evidence-based practices and policy decisions 
relating to tobacco control (Mereu A. et al 2015).
42
Partnerships 
More than half of all organizations had formed partnerships to work on tobacco 
control activities, but cross-sector partnerships were less common. Because tobacco 
use is a complex societal problem, and smoking rates are determined by an array of 
factors- many of which lie outside the influence of the health sector, diverse multi-
sectorial partnerships are key to achieving better outcomes. Diversity improves 
collective understanding and problem solving capacities (Page, 2007). Our findings 
suggest that greater co-operation within, and across, sectors is needed. Success stories 
of partnership and collaboration in other countries provide an excellent example of 
how organizations can engage, share resources and enhance knowledge exchange to 
build capacity and advance the national tobacco control agenda (McDonald and 
Viehbeck, 2007).
Resources for Tobacco Control 
Despite tobacco control being rated as a ‘high’ or ‘very high’ priority for 
organizations, funding adequacy for tobacco control related activities was rated low. 
Our findings are similar to those reported by global survey findings, which showed 
that despite being a high priority, less than 40% of countries (n=65 out of 167) had 
allocated a specific budget for prevention and control of non-communicable disease 
(WHO, 2001). The availability of external sources of funding to support tobacco 
control activities was rated very low by all organizations. Inadequacy funding for 
tobacco control related activities may reflect chronic underfunding of the healthcare 
system as a whole. In the Czech Republic, the health care system has undergone 
major re-structuring since the end of communism in 1989 (Kinkorová J and Topolčan 
O., 2012). Health care spending accounts for 7.2% of the country’s GDP, but it is not 
know how much of this is allocated to specifically to health promotion and chronic 
disease prevention activities that focus on TC (OECD, 2014). The country’s high 
smoking rates, which increased between 2000-2011, and the high incidence of 
smoking related diseases (OECD, 2014) are evidence that chronic disease prevention 
efforts are focused to far down steam to have any real impact on population health.  
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Skills for Tobacco Control 
In terms of core CDP practices, evaluation skills were rated low by all organizations. 
Evaluation is critical to building an evidence-base to inform best practices in CDP 
programming (Milstein, et al 2002). Our findings provide evidence that organizations 
must put a greater emphasis on the importance of evaluation, by dedicated more 
resources to evaluation activities and offering training in evaluation methodology. In 
Canada, Hanusaik et al, similarly found that compared to other core chronic disease 
prevention skills, skills for evaluation were consistently rated as low among 
organizations engaged in chronic disease prevention (2007). 
Tobacco control intervention strategies 
Overall, organizations reported the highest level of involvement in tobacco control 
strategies focused at the individual, rather than population-level interventions. Level 
of involvement was highest for individual-level strategies that focused on public 
education to raise awareness. Although strategies targeting individuals are important, 
these activities tend to be resource intensive and have limited impact on population 
health, largely because they depend on long term individual behavioral change. 
(Frieden TR, 2010). 
In general, population-level strategies require less individual effort, and have the 
greatest impact on population health outcomes (Frieden TR, 2010). For example, 
policies supporting smoke free public spaces change the environmental context to 
makes breathing clean air the default choice, regardless of an individual’s level of 
education, income, access to health care, or other societal factors. An individual 
would have to expend significant effort to not benefit from a cleaner air policy. 
Population level strategies improve not only individual health, but also have economic 
benefits by reducing health care spending and mitigating productively losses (Frieden 
TR, 2010). Less than half of all organizations reported that they were very involved in 
activities that focused on population-level strategies to address tobacco use. The only 
notable difference was that GOV organizations tended to be more involved in policy 
development and advocacy than NGOs. 
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Level of involvement in MPOWER measures 
Evidence-based MPOWER measures outlined by the WHO FCTC are strategies 
countries can use to reduce the demand for tobacco. These measures are inexpensive 
for countries to implement and they work. Organizations reported the highest level of 
involvement in measures that focused on protection from exposure to tobacco smoke 
through creation of smoke free workplaces and public spaces, followed by warning 
about the dangers of tobacco use, and monitoring tobacco use. Half of all 
organizations were ‘very involved’ in measures to promote cessation and treatment 
for tobacco dependence. Just one-third of organizations were ‘very involved’ in 
measured that focused on bans on tobacco advertising, promotion and sponsorship. 
Among he lowest level of involvement was for activities that focus on raising taxes. 
Of all the MPOWER measures, increasing the price of tobacco through higher taxes is 
the single most effective way to encourage tobacco users to quit and prevent children 
from starting to smoke (WHO, 2008). Of all European countries, CR has the lowest 
cigarette prices, due to low excise taxes. While low cigarette prices decrease the 
demand for illegal or contraband cigarettes, cheaper prices are associated with high 
smoking rates, and greater uptake among youth. Higher cigarette prices are 
particularly effective in encouraging cessation and motivate smokers to quit (Ross et a 
2011), particularly young people and those living in poverty (WHO, 2008). Over 
time, simple and effectively implemented tax structures decrease tobacco 
consumption (WHO, 2008). Individuals living in poverty experience the greatest 
health disparities (Cheng et al. 2016). Higher tobacco taxes help decrease health 
disparities by helping people to stop using tobacco and allocate money to essentials 
such as food, shelter and education and health care. This improves families’ health, 
productivity and wage earning capacity by decreasing smoking related illness and 
death (WHO, 2008). 
Barriers to working on tobacco control 
More than half of all organizations reported that insufficient funding and inadequate 
number of staff dedicated to working to tobacco control were the main barriers faced 
by their organization. Lack of political will and competing priorities, as well as 
interference from the tobacco industry were all major barriers. Our findings support 
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previously published reports, which showed that the tobacco industry enjoys a high-
level of political support in the CR and continues to actively influence tobacco control 
policies (Shirane et al 2012)
Limitations
This study had several limitations. One limitation is that data were collected from one 
respondent per organization. Although respondents were carefully selected by the 
head of each organization, and confirmed to be the most knowledgeable about their 
organization’s tobacco control related activities, responses inevitably influence by 
individual views and experiences. Further to this, there are no gold standard measures 
of organizational capacity. Ideally organizational level constructs such as leadership, 
supports, partnership effectiveness, resources and skills should be assessed using 
objective measures. However, within the domain of organizational research, self-
report is the most common method of data collection. While cross sectional data are 
helpful in identifying strengths and gaps in organizational capacity, and provide a 
snap shot of organizations’ involvement in tobacco control activities, longitudinal 
data are needed to establish any causal associations. Future research should focus on 
the association between organizational capacity and level of tobacco control 
nationally, as well as the association with the prevalence of smoking over time. 
Another limitation of this study is that we did not ask organizations about facilitators 
to working on tobacco control related activities. In terms of facilitators, intangible 
outcomes such as trust, mutual respect, transparency, resource sharing and synergy 
that may emerge when organizations work together are valuable assets, which 
contribute to organizational capacity but are difficult to measure. Finally, the extent to 
which these findings are generalizable to other risk factors for chronic disease, such as 
physical activity, healthy eating or alcohol abuse is not known. 
CONCLUSION
In conclusion, this paper provides the first national description of organizational 
capacity and involvement in FCTC measures within the Czech Republic. Our data 
identify areas of TC that need improvement including the need for increased funding 
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and resources dedicated to TC activities, as well as a need for increased involvement 
in population-level strategies and cross sector collaboration. These findings provide 
empirical evidence to local decision makers that may inform strategic priorities and 
help move the TC agenda forward in the Czech Republic. 
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5.0 Cardiovascular disease and nicotine dependence
According to the WHO, all smokers, but especially those with increased 
cardiovascular (CV) risk, should be strongly advised to stop smoking and to avoid any 
exposure to tobacco including passive smoking (WHO, 2008). The risk of an acute 
CV event is high among smokers due to increased coagulation, which leads to 
thrombosis (Kannel et al. 1987; Wilhelmsen 1988; Fuster et al. 1992; Ernst 1994; 
Sambola et al. 2003). 
Every clinician should provide a brief intervention with smokers and intensive 
treatment should be available to those who need it (Fiore et al., 2008). Across the CR 
there are 37-hospital based Centers for Tobacco Dependence. These centres offer 
treatment to tobacco users, which include psychobehavioral intervention and/or 
pharmacotherapy (varenicline, nicotine, bupropion). 
In order to demonstrate the efficacy of intensive treatment of nicotine dependence, we 
conducted the study presented in the following pages. Our cohort consisted of more 
than 3,000 patients who had completed the 12 month follow-up between 2005 and 
2013 (intention-to-treat analysis). We compared one year abstinence rates in the 
following groups of patients: those who only came to the center for the initial 
screening visit + the 12-month follow-up visit, and those who also underwent the 
intervention (screening, intervention and attended at least one 12-month follow-up 
visit). Within the group that underwent the intervention, we also compared patients 
who used pharmacotherapy (varenicline, nicotine, and/or bupropion) versus those 
who did not. Our findings provide strong empirical evidence supporting the efficacy 
of treatment nicotine dependence. 
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4.1 Tobacco Dependence, the Most Important Cardiovascular Risk Factor: 
Treatment in the Czech Republic
The pathophysiological effects of smoking are broad due to more than 4000 
chemicals, including polycyclic aromatic hydrocarbons and oxidizing gases, most of 
which have cardiotoxic effects (Haustein, 2002; Ambrose and Barua, 2004). Nicotine 
is a sympathomimetic agent with potential cardiovascular (increase in heart rate, 
blood pressure and cardiac output) and metabolic effects (increased lipolysis) 
(Benowitz 1998; Ambrose and Barua, 2004). It appears that pure nicotine itself has no 
significant influence on the development of CVD. Nicotine is highly addictive and 
causes addiction to tobacco, which results in inhalation of tobacco smoke with 
noxious agents (Asplund, 2003). The risk of an acute CV event is higher among 
smokers due to increased coagulation, which leads to thrombosis (platelet activation 
and aggregation, activation of coagulation, increased fibrinogen level, increased levels 
of tissue factor, leukocyte count, and D-dimer, and plasma viscosity) (Kannel et al., 
1987, Wilhelmsen, 1988; Fuster et al., 1992; Ernst, 1994; Sambola et al., 2003). Even 
a small dose, including passive smoking, increases platelet aggregation. These 
findings may at least partly explain the higher risk of coronary thrombosis in smokers 
(Lee et al., 1995; Puranik and Celermajer 2003). Active and passive smoking are 
associated with endothelial dysfunction in a dose-dependent manner (Kato et al. 
2006). There is reduced release and availability of NO and the formation of a chronic 
inflammatory condition (leukocytosis, elevated CRP). 
Smoking and hypertension have the same effect on the progression of early 
atherosclerosis (Csányi et al., 2001). Impaired relaxation of arteries observed in an 
animal model, suggests apossible degradation of NO by anionic superoxide of 
cigarette smoke (Török et al., 2000). In vitro studies have demonstrated the 
association between smoking with altered endothelial-derived fibrinolytic and 
antithrombotic factors: t-PA/PAI-I reduction, lower 1-TFPI (tissue factor pathway 
inhibitor), and reduced production of NO (Barua et al., 2002). Nicotine stimulates the 
production of endothelium-derived chemoattractants that enhance the migration of 
smooth muscle cells of blood vessels (Di Luozzo et al., 2005). Endogenous NO 
production may be a protective mechanism against endothelial damage induced by 
smoking (Raveendran et al., 2005). Nicotine increases the level of VEGF mRNA, as 
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well as proteins in the endothelium and may increase the release of TNF-alpha and 
IL-1beta from macrophages (Conklin et al., 2002, Wang et al., 2004). Inhibition of 
endothelial cell migration in the presence of a condensate of cigarette smoke leads to 
a higher probability of developing complications due to incomplete 
reendothelialization (Snajdar et al., 2001). Smoking also has broad endocrine effects 
(Hruskovicova et al., 2013).
Due to CV risk all smokers, but especially those with increased CV risk, should be 
strongly advised not to smoke (diagnosis F17), and to avoid any exposure to tobacco 
including passive smoking (diagnosis E58.7), according to the International 
Classification of Diseases, 10th version (WHO 2008).
Every clinician (physician, nurse, pharmacist) should provide a brief intervention with 
smokers and intensive treatment should be available to those who need it (Fiore et al. 
2008). Treatment that includes a psychobehavioral intervention and pharmacotherapy 
(varenicline, nicotine, bupropion), is offered at Centers for Tobacco-Dependence. 
There are currently 37 hospital-based centers across the Czech Republic. Education of 
Czech physicians, pharmacists and nurses in smoking cessation regularly occurs 
under the Society for Treatment of Tobacco Dependence (info at www.slzt.cz).
METHODS 
To demonstrate the efficacy of intensive treatment, we present a cohort of patients 
who visited the Center for Tobacco Dependence in the Czech Republic. Smokers 
were self referred or referred by a physician to the center for treatment. We compared 
one year abstinence rates in the following groups of patients: those who only came to 
the center for the initial screening visit + the 12-month follow-up visit, and those who 
also underwent the intervention (screening, intervention and attended at least one 12-
month follow-up visit). Within the group that underwent the intervention, we also 
compared patients who used pharmacotherapy (varenicline, nicotine, and/or 
bupropion) versus those who did not.
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The treatment in our center starts with an initial 1-h screening visit. Each patient’s 
level of nicotine dependence is assessed using a series of measures, including the 
Fagerström Test of Cigarette Dependence (FTCD) (Fagerström et al., 2012), CO in 
expired air, the number of cigarettes smoked in the past 12 h, Beck Depression Scale 
II (BDI-II) (Beck et al., 1996), and the Minnesota Withdrawal Scale (Hughes, 2007). 
Within one week of the initial screening visit, patients undergo a 2-h intervention with 
a physician. There is a mean of 4 follow-up visits during the next 12 months. The first 
follow-up visit usually occurs within 2 weeks of the intervention, and monthly 
thereafter.
The intervention with a physician is performed individually or in small groups with 4-
5 individuals. Following the intervention, based on our recommendation, the patient is 
offered either varenicline, nicotine replacement therapy or bupropion and/or a 
combination. We set a quit date. Follow-up visits take about 30 min and include 
checking the patient’s weight, blood pressure, and heart rate. We measure CO in 
expired air and discuss withdrawal symptoms, as well as we check the treatment. The 
visit schedule and intervention structure are described in Table 5.
This analysis was approved by the Ethics Committee of the General University 
Hospital in Prague, registration FWA 00003027 – according to the Office for Human 
Research Protections, U.S. Department of Health and Human Services, under No. IRB 
00002705. The General University Hospital is registered under No. IORG 0002175.
Standard descriptive statistics were used to characterize the sample data set. Statistical 
significance of differences in 12-month abstinence rate by gender and the type of 
pharmacotherapy used were assessed by Fisher- exact test. Statistical significance of 
differences in baseline characteristics between groups of patients who had undergone 
the intervention and those who did not was assessed by Mann-Whitney test or Pearson 
Chí-square test. A significance level of alpha = 0.05 was used.
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RESULTS
Our analysis included 3532 patients who had completed the 12 month follow-up 
between 2005 and 2013 (intention-to-treat analysis). The abstinence rate was 34.3 % 
in all patients including those who had attended only the initial screening and the 12-
month follow up visit, compared to 38.2 % among those who had also undergone the 
intervention (initial screening visit, intervention and at least the 12-month follow-up 
visit). For more detail see Figures 1 and 2, and Table 6. In Table 7 selected CV risk 
factors are compared.
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Table 5. Visit schedule for patients of the Center for Tobacco-Dependence (Králíková 
et al., 2014). 
Screening visit
Vital signs, weight, height, heart rate, blood pressure, personal history and social 
background, CO in expired air, withdrawal symptoms, and other tests
Intervention visit
(Usually within one week of the initial screening visit)
Heart rate, blood pressure, CO in expired air, withdrawal symptoms. Intervention structure:
Introduction. Explain to the patient that the intervention is meant to be interactive and that 
they should feel free to discuss how they are feeling and ask questions at any time.
Patient’s expectations and how the treatment will proceed.
Patient’s smoking history including the total the number of cigarettes smoked per lifetime, 
the association between smoking and other routine activities (e.g. having a coffee).
Patient’s experiences with previous attempts to quit and reasons for relapse.
The principles of nicotine dependence. How smoking is a learned behavior and changes that 
occur in the brain.
Identifying with being smoke-free and enjoying it.
Specific health consequences of smoking based on the patient's condition to help improve 
motivation, including improved mental health.
Provides brochure titled “My Way to Smoke-Free”.
Patient’s decision to quit smoking, including readiness, confidence in their ability to 
succeed, and their main source motivation. Responses are based on a 10 point-likert scale 
and responses may be revisited again at a later date.
The principal behind measuring breathe CO. Patient’s specific CO values and how this 
relates to estimated nicotine intake from cigarettes.
The importance of behavioral support and typical smoking situations they will encounter 
(coffee, alcohol, smoking environment, food, stress, peace/rest, waiting, in the car, in the 
restaurant...). Work with the patient to prepare smoke-free solutions in advance and 
encourage them to look forward to these situations.
The importance of rewarding yourself for small successes.
Strategies to prevent weight gain, as well as the connection between smoking and stress.
Alternative relaxation techniques (deep breathing, yoga, Jacobson, etc).
Possible barriers to quitting, and how being aware of these barriers can decrease the 
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likelihood of relapse.
The importance of social support, as well as strategies for living and/or working with other 
smokers. How to refuse a cigarette.
Withdrawal symptoms.
The principles of physical dependence, and the specific FTCD score of the patient. Show 
video demonstrating the effect of smoking on dopamine release.
Pharmacotherapy options. Drug’s mechanism of action and any possible side effects.
The cost of pharmacotherapy and possibility of reimbursement.
Indication for use of pharmacotherapy and the recommended length of treatment.
Quit date, highlighting that any smoking is smoking.
Date of the next visit (usually within two weeks after the initial intervention).
Follow up visits
(Based on the patient needs, but usually within 2 weeks of the quit date, then about 3x 
monthly, then at 6 and 12 months after the quit date)
Heart rate, blood pressure, CO in expired air, withdrawal symptoms collected at each visit
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Table 6. Selected characteristics of patients of the Center for Tobacco Dependence 









Male 1,526 (50.1 %) 255 (52.1 %)
0.412
Female 1,517 (49.9 %) 234 (47.9 %)
Age at first visit
≤ 29 475 (15.6 %) 92 (18.8 %)
0.057
30-39 841 (27.6 %) 113 (23.1 %)
40-49 550 (18.1 %) 80 (16.4 %)
50-59 581 (19.1 %) 110 (22.5 %)
≥ 60 596 (19.6 %) 93 (19.0 %)
Education
basic 288 (9.5 %) 59 (12.1 %)
0.002
secondary 1,905 (62.6 %) 328 (67.1 %)
university 850 (27.9 %) 102 (20.9 %)
Daily smoked cigarettes
Up to 10 253 (8.4 %) 62 (13.0 %)
0.018
11-20 1,578 (52.1 %) 233 (48.7 %)
21-30 750 (24.8 %) 110 (23.0 %)
31-40 332 (11.0 %) 51 (10.7 %)
> 40 116 (3.8 %) 22 (4.6 %)
FTCD2
0-1 points 144 (4.8 %) 40 (8.6 %)
0.0082-4 points 823 (27.4 %) 118 (25.3 %)
5-7 points 1,345 (44.7 %) 200 (42.8 %)
8-10 points 697 (22.9 %) 109 (23.3 %)
BMI (kg/m2)3 25.4 (19.5 ; 34.5) 25.5 (18.9 ; 35.8) 0.976
% body fat 28.0 (14.3 ; 42.4) 28.2 (13.4 ; 43.2) 0.421
Waist-to-Hip Ratio (%) 87.6 (71.7 ; 104.6) 87.2 (71.3 ; 105.6) 0.730
CO (ppm)4 17.0 (1.0 ; 38.0) 15.0 (0.0 ; 39.0) 0.004
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COHb (%) 5 3.0 (0.3 ; 6.9) 2.8 (0.1 ; 6.9) 0.020
Patients with a complete record, who passed the intervention = at least screening, 
intervention and 12-month follow-up visit (N=3,043)
Patients with incomplete record (screening and 12-month follow up, in case of loss to 
follow-up, patients were considered smokers at 12 months) (N=489)
1 Differences tested according to the Mann-Whitney U test or Pearson Chí-square test; 
2 Fagerström Test of Cigarette Dependence; 3 body mass index; 4 carbon monoxide; 5 
carbonylhemoglobin
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Table 7. Cardiovascular characteristics of patients who stopped smoking (non-
smokers) and patients who continued to smoke (smokers) (Králíková et al., 2014). 
 
Characteristics Visit







Weight Baseline 1,158 77.0 (45.0-135.3) 1,857 75.8 (41.6-187.0)
12 months 
follow-up
1,094 82.9 (45.0-147.0) 100 83.4 (50.0-133.0)
Pulse Baseline 1,145 72 (41-119) 1,835 72 (45-116)
12 month 
follow-up
879 72 (42-154) 84 72 (56-107)
Systolic 
pressure
Baseline 1,150 125 (85-190) 1,850 123 (73-220)
12 month 
follow-up
885 125 (85-210) 85 126 (90-180)
Diastolic 
pressure
Baseline 1,150 80 (50-125) 1850 80 (45-131)
12 month 
follow-up
884 80 (50-111) 85 80 (54-105)
1 Many missing data in the group of smokers are due to a loss to follow-up. In such a 
case the patient was considered to be a smoker.
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Pharmacotherapy (any kind) significantly increased the abstinence rate. The majority, 
81 % of patients used some form of pharmacotherapy. Among patients who had used 
some form of pharmacotherapy the abstinence rate was 43.4 %, compared to 15.9 % 
among patients who tried to stop smoking without pharmacotherapy (Fig. 3).
Although health was the most frequent reason to stop smoking – in 68 %, only 28 % 
of patients said their physician had recommended they visit our center. Most patients 
learned about our center by way of media, including Internet – 49%, followed by the 
recommendation of other patient’s – 18%. The rest learned about our center from 
other sources (5 %). For a more detailed description of our patients and results, 
including abstinence rates according to pharmacotherapy used, psychiatric 
comorbidity or CV risk factors see our other publications (Zvolska et al., 2012; 
Kralikova et al., 2013; Stepankova et al., 2013; Kmetova et al., 2014).
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Figure 1. 12-month abstinence rate among patients of the Center for Tobacco- 
Dependence in the Czech Republic between 2005 and 2013 (Králíková et al., 2014). 
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Figure 2. 12-months abstinence rate after in patients of the Centre for Tobacco-
Dependent who passed intensive intervention (Králíková et al., 2014). 
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Figure 3. 12-months abstinence rate in all patients of the Centre for Tobacco-
Dependent according to pharmacotherapy use (Králíková et al., 2014). 
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DISCUSSION
Stopping smoking without any help has a low long-time success rate, about 5 % 
(Fiore et al., 2008). Intensive treatment may increase the number of former smokers 
substantially. Brief smoking cessation interventions are still not a usual part of clinical 
practice. Eighty percent of Czech physicians report asking about tobacco use and 
advising patients to stop smoking, but the next steps of the brief intervention are 
rarely followed. It is necessary to offer help in quitting (recommend treatment or refer 
the patient to a Center for Tobacco-Dependence), and to plan follow-up visits 
(Kralikova et al., 2011). For a center located in a large hospital we would expect more 
than 28 % of patients would be referred based on a physician’s recommendation. The 
majority of smokers learn about intensive treatment possibility from sources other 
than their physician, which may suggest that brief smoking cessation intervention is 
not regularly used in clinical practice.
Also the diagnosis Z58.7 (passive smoking) may be a teachable moment, if used. 
Currently, this diagnosis is not used at all in the Czech Republic. Only 1.5 % of 
hospitalized patients was diagnosed F17 (tobacco dependence) in 2011 (Zvolsky et al. 
2012) – despite a 30 % smoking prevalence in the population with about 80 % of 
smokers being dependent (Sovinova and Csémy, 2013). A similar situation was 
described in psychiatric care in the USA with an 88 % prevalence of tobacco use 
among psychiatric patients, while only 2 % were diagnosed. Among psychiatric 
patients who smoke, even more than 80 % were dependent (Peterson et al. 2003).
Our results are comparable with international results. For patients receiving outpatient 
treatment at the Nicotine Dependence Center (NDC) of the Mayo Clinic in 
Minnesota, USA, the 6-month smoking abstinence rate has been reported ranging 
from 22 % to 25 %. The 1-year smoking abstinence rate for patients who enter the 
residential treatment program at NDC is reported to be 52 %. But, one limitation is 
that abstinence is verified there mainly by telephone only (Hurt et al. 2009).
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Choice of medication depends on the intensity of addiction, but also on the patient’s 
previous experiences, preferences, financial options, etc. Interestingly there is a fear 
of adverse effects with smoking cessation pharmacotherapy (either nicotine, 
varenicline or bupropion) among patients as well as physicians, though no adverse 
cardiovascular (Mills et al., 2013) or neuropsychiatric effects (Thomas et al., 2013) 
have been proven.
CONCLUSION
Smoking cessation intervention is a missed opportunity in cardiology despite many 
pathophysiological CV links that could be used to enhance patients’ motivation to 
stop smoking. The possibility of intensive treatment of tobacco dependence could be 
used more broadly especially in CV patients or patient with elevated CV risk.
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6.0 Tobacco use among the critically ill 
Among tobacco user, those who suffer from chronic health conditions and continue to 
smoke may be among the most heavily addicted. Despite poor health and the 
knowledge that cessation would bring important health benefits many of these 
tobacco users are unable to stop smoking (Woodward M and Tunstall-Pedoe 1992; 
Archbold et al., 1995; van Berkel et al., 1999). This may not be due to lack of 
motivation, but rather speak to their level of nicotine dependence (West, 2004). 
Among patients that suffer from chronic health conditions, there is a need for more 
consistent screening protocols and referral procedures to help patients who may need 
treatment for nicotine dependence. This represents an important gap in the Czech 
health care system. In order to demonstrate point, we conducted a study focused on 
patients with end-stage lung disease. We conducted a cross-sectional survey of 
urinary cotinine to assess tobacco exposure in 203 patients in the Lung Transplant 
Program in the Czech Republic. We measured urinary cotinine in 163 patients prior to 
inclusion on the transplantation waiting list, and 53 patients post bilateral lung 
transplantation. 
Our findings provide evidence that smoking resumption may be an under recognized 
risk for lung transplantation recipients, particularly among patients with chronic 
obstructive pulmonary disease. More rigorous screening, as well as support and 
treatment to stop smoking among these patients are needed.
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6.1 Continued Smoking in Lung Transplant Patients
Cigarette smoking is the single greatest modifiable risk factor for death and illness 
due to lung disease (U.S. Department of Health and Human Services, 2004). The 
benefits of smoking cessation are well established. Despite advances in medical 
therapy, lung transplantation (Tx) remains the best treatment option for patients with 
end-stage lung disease. The demand for lung transplantation greatly exceeds 
availability, yet developing rigorous selection criteria and methods to identify suitable 
transplant recipients continues to present unique challenges.
Patients who actively abuse drugs, alcohol or use tobacco products are routinely 
excluded from Tx waiting lists (WL), until they have been abstinent for at least 6 
months. Among patients with alcoholic liver disease, many programs require a 
minimum of 6 months of abstinence from alcohol before placement on the transplant 
waiting list (Lucey et al., 1997). Similar to alcohol dependence, tobacco dependence 
is a chronic disease characterized by relapse and remission (Center for Tobacco 
Research and Intervention, 2015). 
Pharmacological treatment combined with intensive counseling has been shown to 
improve smoking cessation rates (Dornelas et al., 2000; Jorenby et al., 1999; 
Gonzales et al., 2006). While the risk of smoking on post lung Tx outcomes have not 
yet been adequately described (Corbett et al., 2012), evidence in liver, heart and renal 
Tx patients suggest that smoking is associated with higher incidence of post-Tx 
complications and mortality (Vos et al., 2010; Herrero et al., 2005; Vallejo et al., 
2005; Pungpapong et al., 2002; Botha et al., 2008; Nguyen et al., 2007). Despite 
efficacy of current cessation therapies, compliance among transplant recipients is 
often poor, with 10–40% returning to smoking post- Tx (Corbett et al., 2012). Few 
centres actively screen patients for tobacco exposure or offer cessation support to 
patients, particularly post Tx (Vos et al., 2010). Many centres rely on self-reported 
smoking status, which has previously been shown to be unreliable. (Nguyen et al., 
2007; Attebring et al., 2001; Woodward M and Tunstall-Pedoe 1992). 
Despite the severity of their illness and the knowledge that quitting would have 
important long-term benefits, many patients continued to smoke (Woodward M and 
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Tunstall-Pedoe 1992; Archbold et al., 1995; van Berkel et al., 1999). This may not be 
due to the lack of motivation to stop smoking, but rather a matter of dependence for 
these patients (West, 2004). Furthermore, despite lung Tx candidates’ reliable self-
reported disclosure of active smoking, it is unlikely that their survival may depend on 
inclusion on the Tx WL. Due to the limited number of suitable donors and the high 
demand for Tx, it is important that centres are able to detect patients who deceptively 
report smoking behaviour in order to select patients who will have the best outcomes 
long term. The aim of this study was to determine the prevalence of smoking among 
patients post lung Tx, as well as prior to inclusion on the Tx WL, and to offer 
treatment of tobacco dependence to smokers. The only lung Tx center in the CRis 
located at the University Hospital in Motol. The centre has performed about 20 lung 
Tx per year since 1997. To date, physicians in the CRhave relied solely on self-
reported smoking status. This study is the first to measure urinary cotinine levels prior 
to inclusion on the Tx-WL and post lung-Tx among patients in the Czech Republic.
METHODS
Between January 2009 and April 2012, we conducted a cross sectional survey of 
urinary cotinine levels to assess tobacco smoke exposure in 203 patients in the Lung 
Transplant Program. The purpose was to biochemically validate self-reported 
smoking status in these patients and determine if ongoing screening might be 
necessary. All patients had been diagnosed with end-stage lung disease and were 
cared for by the Department of Pneumology, 2nd Faculty of Medicine, Charles 
University in Prague, and the University Hospital in Motol, Czech Republic.
Urine samples were obtained from patients at routine visits. 163 patients were tested 
prior to inclusion on the lung transplant WL. 53 patients were tested post-Tx as bi-
lateral lung recipients cared for by Lung Transplant Centre, 3rd Department of 
Surgery, 1st Faculty of Medicine, Charles University in Prague, and Motol University 
Hospital, Czech Republic. 13 patients were tested both prior to inclusion on the WL 
and post-Tx.
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Prior to inclusion on the Tx-WL, patients had to meet the following criteria: the 
terminal state of pulmonary disease with expectancy survival of 12–18 months; the 
dependence of oxygen inhalation from oxygenator; and exhaustion of all other 
conservative treatment options. Patients had to meet standard criteria for specific 
diagnoses and avoid all absolute contraindications, including: malignant tumor, 
progressive neuromuscular disease, severe systemic disease or infection (HIV, 
hepatitis B or C), multi organ failure, ideal body weight < 70% or > 130%, long term 
corticoids treatment > 20mg Prednisone/ day, smoking or drug use during last six 
months, acute infection, psychosocial instability, or diabetes mellitus with organ 
complications. Other relative contraindications included: age > 65, the need for 
invasive ventilation, cardiac disease, or renal disease with creatinine clearance < 
50mg/ml/min. Prior to inclusion on the WL, all patients in our sample met the 
inclusion criteria, but only had to prove they had been smoke-free during the last 6 
months. All patients were advised to avoid active and passive smoking. This was 
validated by a negative urinary cotinine result, which was an obligatory parameter for 
the inclusion on the transplant WL. Among patients who had a positive or borderline 
result, passive smoking was discussed, and they were tested again at subsequent 
visits. All patients were asked about the use of nicotine replacement therapy or 
nicotine in other forms (none reported). Two patients reported using electronic 
cigarettes.
Between January 2009 and April 2012, all lung Tx recipients and patients prior to 
inclusion on the Tx-WL were eligible to be included in the study. All post-Tx patients 
were tested for urinary cotinine as a part of annual Tx follow up. The data including 
demographic characteristics and diagnosis was obtained from patients’ charts (see 
Table 1). This study was approved by the ethics committee at University Hospital in 
Motol, Czech Republic.
Urinary cotinine (COT) was measured as a marker of smoking. Urinary cotinine 
levels (COT) were assessed by semiquantitatively urine enzyme immunoassay (DRI® 
Cotinine Assay, Microgenics Corporation, Fremont, CA, USA) (West, 2004; Wilcox 
et al., 1979). Based on urinary cotinine levels, patients were categorized as positive (≥ 
500 ng/ml), negative (< 50 ng/ml), or borderline (50-499 ng/ml), according to their 
level of tobacco exposure. In the case of a positive or borderline result, the measure 
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was confirmed by LCMS/MS (Applied Biosystems, 3200 Q Trap®, Singapore, 
Singapore) (Wilcox et al., 1979; Jones-Burton et al., 2007; Chambers et al., 2001; 
Urakawa et al., 1994; Chadwick and Keevil 2007; Zielińska-Danch et al., 2007). 
Patients with a borderline or positive result were tested again at subsequent visits. 
Previously established urinary cotinine cut-off points were used to categorize patients 
as negative, borderline or positive for tobacco smoke expose (Zielińska-Danch et al., 
2007). These cutoffs were established by Zielińska-Danch et al. to distinguish non-
smokers, passive and active smokers. A brief cessation intervention (up to 10 
minutes) was conducted with all smokers, as well as the recommendation to visit the 
Centre for Tobacco-Dependence.
Statistical analyses were performed using MedCalc for Windows, version 12.4.0 
(MedCalc Software, Mariakerke, Belgium). For post-Tx patients and patients prior to 
inclusion on the WL, means and standard deviations were calculated for continuous 
variables, whilst frequencies and percentages were calculated for the categorical 
variables.
RESULTS
The majority of patients in both observed groups suffered from chronic obstructive 
pulmonary disease (COPD) or idiopathic pulmonary fibrosis. Patients with Cystic 
Fibrosis were on average 25.6 years younger than patients with other diagnoses 
(Table 8).
Among patients prior to the inclusion on the Tx waiting list, 4.9% (8/163) had at least 
one positive urinary cotinine test corresponding to active smoking (Table 9). Two 
patients reported using electronic cigarettes. Another 6.1% of patients (10/163) had 
borderline results, and the test was repeated. In the case of positive or repeated 
borderline tests, patients were not included to the WL until they had been smoke-free 
(negative test for urinary cotinine) for at least 6 months. Prior to inclusion on the Tx-
WL, all patients were tested for cotinine in urine.
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The prevalence of positive urinary cotinine among patients post-Tx was 15.1% (8/53). 
An additional 3.8% of post-Tx patients (2/53) had borderline results. One year post-
Tx, 80% of all patients were tested for urinary cotinine during the observed period at a 
median of 1.4 (0.95 – 2.64) years. There was no known selection bias.
Regarding patients’ positive and borderline urinary cotinine levels, corresponding to 
active smoking, the prevalence of cotinine was consistently higher among patients 
with COPD at both time points, compared to patients with other diagnoses (Table 10). 
All patients who tested positive for urinary cotinine levels were offered smoking 
cessation support, but only one Tx patient sought treatment for tobacco dependence at 
the Centre for Tobacco Dependent. That patient did not quit smoking.
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Table 8. Demographic characteristics of lung transplant recipients’ post- transplant 
and prior to inclusion on the transplant waiting list in the Czech Republic 2009-2012 





Gender (% male) 67% 62%








COPD group 69 (42.3%) 26 (49.1%)
Non-COPD group 94 (57.7%) 27 (50.9%)
CF; Cystic Fibrosis; Pre-WL; pre-wait list; Post-Tx; post-transplant; COPD; Chronic 
Obstructive Pulmonary Disease.
70
Table 9. Urinary cotinine concentrations among lung transplant (Tx) patients’ post-
Tx and prior to inclusion on the waiting list in the CR2009-2012. 80% of all patients 










95% CI 0.821 to 0.921
81.1% (43/53)
95% CI 0.685 to 0.893
Borderline
(50 ≤ X < 500 ng/ml)
6.1% (10/163)
95% CI 0.033 to 0.108
3.8 % (2/53)




95% CI 0.025 to 0.094
15.1 % (8/53)
95% CI 0.078 to 0.269
Pre-WL; pre-wait list; Post-Tx; post-transplant 
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Table 10. Comparison of urinary cotinine levels among patients with COPD & 
Emphysema and patients with other diagnosis post-lung Tx and prior to inclusion on 
the Tx waiting list (Zmeškal et al., 2015).


































95% CI 1.92 to 637.37
P-value 0.016
COPD; Chronic Obstructive Pulmonary Disease, Post-Tx; post-transplant, Pre-WL; 
pre-wait list
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Post-Tx, the prevalence of smoking resumption was 15% (8/53), based on positive 
urinary cotinine levels. The highest prevalence post-Tx was among patients with 
COPD, with 38.5% (10/26) having positive or borderline urinary cotinine levels 
corresponding with active smoking. All patients who tested positive for urinary 
cotinine levels were offered smoking cessation support.
The odds of smoking resumption was not different for men or women. There was a 
trend towards women tending to be more likely to have a positive or borderline 
urinary cotinine result prior to the inclusion on the Tx WL, but the difference was not 
significant.
The odds of smoking resumption were higher among patients with COPD, compared 
to patients with other diagnoses, at both time points. Prior to inclusion on the WL, the 
odds of smoking resumption was 4.13 times higher among patients with COPD (Table 
9), and 35 times higher post-Tx, compared to patients with other diagnoses.
DISCUSSION
Our most remarkable finding was the high prevalence of smoking resumption post-
Tx, particularly among patients with COPD. Despite the fragility of their condition, 
15% of all tested lung Tx recipients had urinary cotinine levels corresponding to 
active smoking; a further 3.8% had borderline results. Compared to patients with 
other diagnoses, patients with COPD were 35 times more likely to resume smoking 
post-Tx.
Our findings are similar to those of Vos et al. who found that 11% of lung Tx 
recipients self-reported smoking resumption post transplantation (Vos et al., 2010). 
Similarly, the prevalence was higher (23%) among patients with emphysema due to 
COPD (Vos et al., 2010). Risk factors, including shorter cessation period prior to 
transplantation, lower socioeconomic status, exposure to second-hand smoke, 
emphysema, and death of a spouse were all associated with a higher likelihood of 
smoking resumption post-Tx (Vos et al., 2010). In a group of 331 lung Tx patients, 
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Ruttens et al. found that the prevalence of post-Tx smoking was 12%, and they 
identified peer group smoking as an important risk factor for smoking resumption 
(Ruttens et al., 2014).
Over a period of 13 years, Botha et al. covertly assessed smoking habits among 
cardiac transplant patients (2008). They found that 27% tested positive for urinary 
cotinine levels corresponding to active smoking at least once post transplant; 15% 
tested positive repeatedly (Botha et al., 2008). Post cardiac transplantation, smoking 
shortened median survival and was the most significant determinant of overall 
mortality (Botha et al., 2008). Among liver transplant recipients, Lee et al. found that 
12% self-reported smoking resumption post surgery (Lee et al., 2009). Bright et al. 
similarly found that 17% of liver transplant recipients’ self-reported ongoing tobacco 
use (Bright et al., 2010). They also found that self-reported smoking behaviour was 
not the most reliable measure, as 11% of liver transplant recipients who denied 
tobacco use, had serum cotinine levels that corresponded to active smoking (Bright et 
al., 2010). Among renal transplant recipients, Nguyen et al. found that 34% of 
patients with serum cotinine levels corresponding to active smoking, claimed to be 
non-smokers (Nguyen et al., 2007).
Ensuring that candidates are abstinent prior to transplantation is important, but this is 
only half of the equation. Few centres actively screen patients for tobacco exposure or 
offer cessation support to patients, particularly post transplantation (Vos et al., 2010). 
Until 2008, the Pneumology Clinic and the Lung Transplant Centre in Prague relied 
solely on patients’ self-reported smoking status. No further validation was deemed 
necessary, as those patients were considered to be too ill to continue smoking. We 
found that 4.9% of transplant candidates prior to inclusion on the WL tested positive 
for urinary cotinine levels corresponding to active smoking; a further 6.1% had 
borderline results. Those findings clearly speak to the degree of nicotine dependence 
among some patients, the need for active screening, and the importance of offering an 
ongoing smoking cessation support to patients both pre- and post-Tx.
Despite the fact that patient compliance with cessation measures is often poor, this 
problem may be perpetuated by a number of factors. Beyond self-reported smoking 
status, few centers actively screen for tobacco use, or collect a comprehensive 
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smoking history on their patients. Factors, such as the duration of abstinence period, 
quit attempts, the age of initiation, demographics, behavioural and psycho- 
sociological factors have all been shown to influence cessation (Caponnetto et al., 
2008; Dobbels et al., 2006). The implementation of a more rigorous screening 
program will help centres identify patients who may benefit from an ongoing 
cessation support, and those patients who may be the most promising candidates for 
Tx.
To date, pharmacological treatment for nicotine withdrawal symptoms combined with 
intensive counseling have been shown to improve quit rates (Dornelas et al., 2000; 
Jorenby et al., 1999; Gonzales et al., 2006). Our findings underscore the need for 
physicians to proactively address smoking behaviour and screen patients for smoking 
at each visit. Unfortunately, many physicians are ill prepared to talk to their patients 
about smoking and, therefore, do not intervene (Roddy et al., 2004). While physicians 
need support, information and training to effectively intervene, there is also the need 
for a reliable system of tobacco treatment centres, where patients can be referred to in 
order to receive the specialized cessation support they need.
Limitations of the current study include: a small sample size (dictated by the number 
of lung Tx in the Czech Republic, which is around 20 per year) and the availability of 
sociodemographic characteristic (e.g. socioeconomic status, marital status, stress/ 
anxiety, depression, etc.), as well as more detailed information about patients’ 
smoking histories (e.g. quit attempts, the duration of abstinence, the age of initiation, 
smoking frequency, the degree of nicotine dependence, etc.). Without proper screen 
protocols in place, the medical staff cannot proactively identify patients who may 
have relapsed, or refer them to appropriate cessation supports. Another limitation is 
that only 80% of all patients were tested one year post-TX in the observed period. 
Despite results of a pilot study that showed the importance of an ongoing screening, 
testing may not have been perceived as a priority by staff, and, in some cases, samples 
were never collected. In some cases, patients did not show up for follow-up visits, or 
there were issues relating to handling and processing samples.
All biochemical tests can trigger false results. In the case of urinary cotinine, the use 
of nicotine replacement therapy or ingestion of nicotine in any form will result in a 
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positive test, even though the patient may have quit smoking. In the case of a false 
positive result, the patient should be questioned about any tobacco smoke exposure in 
more detail, and another test should be conducted at a subsequent visit. All patients in 
the study were asked about the use of nicotine replacement therapy or the use of 
nicotine in any form; none was reported. Two patients reported using electronic 
cigarettes. The biological cut offs used included a range that would account for even 
higher levels of exposure to environmental tobacco smoke, so there is little likelihood 
of a false positive result due to passive smoking. A false negative result is also 
possible in the case where enough time has passed for cotinine to be eliminated from 
the patient’s system prior to the test, but this result is not likely in heavy smokers.
CONCLUSION
Despite the fragility of their condition, smoking continues to be an issue for many 
patients with end stage lung disease. The prevalence of smoking among patients post 
lung Tx, as well as prior to the inclusion on the Tx-WL, provides evidence that an 
ongoing screening is necessary to detect smoking resumption. The implementation of 
routine screening protocols may help centers identify those candidates who are likely 
to have the best outcomes post transplantation.
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7.0 Translating research into practice
There is strong evidence supporting the use of brief intervention with smokers at each 
clinical contact (success rate of 5-10 %).  Intensive treatment (success rate >30%) 
should be available to those who need it. Tobacco related comorbidities and treatment 
of dependence are relevant to clinicians of all disciplines, yet brief intervention is still 
not part of standard clinical practice in the CR. 
In order to translate the latest evidence into practice clinical practice, medical 
professionals from all disciplines must recognise tobacco dependence as a disease 
(code F17), and incorporate tobacco dependence treatment into clinical practice 
guidelines (CPG).  In order to highlight this critical gap practice, we conducted a 
review of all CPG documents relating to cardiovascular and respiratory diseases, as 
well as cancer from 20 selected medical professional societies within the CR. We 
searched each document for keywords "smoking", "tobacco" and "nicotine addiction”. 
Our findings provide evidence that despite the clinical significance of smoking, the 
majority of CPG did not adequately address tobacco dependence and its treatment, 
representing a major gap in translating research findings into clinical practice.
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7.1 Treatment of Tobacco Dependence: A critical gap in Czech Clinical Practice 
Guidelines. 
Smoking is the leading cause of preventable death globally (WHO, 2008). 
Cardiovascular diseases (CVD) are the most common cause of death among smokers. 
In the CR, about 2,000 more people die annually due to CVD than to lung cancer, the 
most common form of cancer caused by smoking (Peto R, et al., 2015). Overall 
mortality in the CR due to smoking is about 14,000 people a year (Peto R, et al., 
2015). Compared to developed Western countries of the EU, the prevalence of 
smoking in the CR is high ‒ 29% (33% men, 24% women) (Cifkova, 2006; Sovinová 
et al., 2012). The prevalence of smoking in the CR undoubtedly contributes to the 
country’s high cardiovascular mortality rate, which in 2001 was almost two times 
greater than that of other European countries (15 European Union member states 
before 2004) (Molarius, et al., 2001). 
Tobacco dependence is a chronic disease characterized by relapse and remission, 
which can be reported according to the International Classification of Diseases 10 
(ICD-10) code F17 (Hughes et al., 2004; WHO, 2011). The quit rate among smokers 
who stop without help or using methods with placebo effect is about 2‒5% after one 
year (Hughes et al., 2004; Royal College of Physicians of London, 2000). According 
to the WHO, all physicians should provide a brief intervention for tobacco use to a 
patient at each clinical contact. The success rate of brief intervention is 5‒10% (Fiore 
et al., 2008). A brief intervention consists of 5 points known as the “5 A’s”. The 
intervention involves asking the patient about tobacco use, advising the patient to quit, 
assessing readiness to quit, assisting the patient in quitting, and arranging for follow 
up (Fiore et al., 2008). People unable to quit should be recommended to receive 
intensive specialized treatment. The success rate with intensive treatment 
(psychobehavioural therapy and pharmacotherapy) provided by specialized Centres 
for Tobacco-Dependent (CTD) in the CR is over 30% after one year (Králíková et al., 
2013; WHO, 2014).
Brief intervention with patients who smoke is still not standard clinical practice in the 
CR. Eighty percent of Czech physicians ask about tobacco use and advise patients to 
quit. Beyond this, subsequent parts of the brief intervention are delivered to smokers 
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i.e. assessing readiness to quit, assisting the patient to quit, and arranging for follow 
up (Králíková et al., 2011).
According to the National Institute of Health, clinical practice guidelines (CPG) are 
systematically developed statements to assist practitioners and patients in making 
appropriate decisions about health care for specific clinical circumstances (Field and 
Lohr, 1992). CPG help support the transfer of research knowledge into clinical 
practice. Tobacco related comorbidities and treatment of tobacco dependence are 
relevant to clinicians of all disciplines. According to the WHO there should be a 
systematic approach for incorporating brief tobacco interventions into primary health 
care services (WHO, 2014).
Our aim was to determine whether or not tobacco dependence treatment 
recommendations were included in selected CPG documents for cardiovascular and 
respiratory diseases, cancer and related comorbidities from various medical 
disciplines.
METHODS
In the Czech Republic, there are approximately 120 medical professional societies. 
Most of these societies are part of the Czech Medical Association of Jan Evangelista 
Purkyně (CzMA) (CMA JEP 2014). We selected 20 societies (Table 11) in the fields 
of internal and general medicine or oncology that had published CPG on their 
websites. These documents were freely accessible online as of December 2, 2013. We 
then selected current CPG from each society that addressed education, treatment or 
prevention of dis- eases related to smoking as a risk factor. We excluded CPG that 
addressed acute conditions, diagnostics only, laboratory methods, or administration. 
We searched for keywords “smoking”, “tobacco” and “nicotine addiction” in the full 
text of 94 selected CPG documents. Documents were reviewed to determine if 
smoking was mentioned as a risk factor (RF) or if they included any 
recommendations relating to intervention or treatment.
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According to the results of the keyword search, we classified the CPG documents into 
four groups: CPG with no mention of smoking; CPG that reported smoking as a RF; 
CPG that included two word recommendation to stop or minimize smoking; CPG 
with a comprehensive approach that included recommendation to use a brief 
intervention, a link to the Centres for tobacco-de- pendent, or guidelines for tobacco 
dependence treatment (Králíková et al., 2015; Society for Tobacco Dependence 
Treatment, 2014).
RESULTS
Among all CPG documents related to cardiovascular and respiratory diseases as well 
as cancer, 27.7% (26/94) did not mention smoking. 16% (15/94) of documents listed 
smoking among risk factors. 42.5% (40/94) of CPG included some recommendation 
to stop or minimize smoking (e.g. “smoking ban”). 13.8% (13/94) of CPG 
recommended a comprehensive approach to treatment or prevention of tobacco use.
CPG documents which included no mention of smoking in the diagnosis and 
treatment included venous thromboembolism, diabetic retinopathy, atrial fibrillation, 
chronic pulmonary hypertension, obesity, cystic fibrosis, interstitial lung disease, 
tuberculosis, malignant pleural mesothelioma, chronic pancreatitis, colorectal cancer, 
malignant lymphoma, hepatocellular cancer, and dyslipidemia.
Many CPG documents mentioned smoking only as a RF in the introduction, and 
rarely mentioned tobacco use in terms of primary and secondary prevention.
Smoking related recommendations were often included in the non-pharmacological 
treatment section of CPG. The most frequently mentioned smoking related 
recommendations, in descending order, included; smoking ban, cessation, abstinence, 
elimination, and quit smoking/stop smoking. The terms smoking minimization, 
avoiding smoking, warning against smoking, smoking omission, give-up smoking, 
and restriction on smoking were each mentioned only once in the 94 CPG documents 
we reviewed. Only two professional societies had a link to the Guidelines for Tobacco 
Dependence Treatment on their website (Czech Society of Cardiology and Czech 
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Society for Oncology). The Prevention of Cardiovascular Diseases in Adults ‒ Joint 
Guidelines of Czech Professional Societies (2005) is the only CPG document that 
fully addressed tobacco dependence treatment (Cífková et al., 2005)
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Table 11. Tobacco dependence treatment recommendations in selected Clinical 
Practice Guidelines (CPG) of medical professional societies in the Czech Republic 
(Zvolská et al. 2017).
Medical professional society
(n = 20)











Cerebrovascular Section of the 
Czech Neurological Society
0 0 6 1 7
Czech Society of Angiology 1 0 1 0 2
Czech Diabetes Society 2 3 4 1 10
Czech Society of Internal 
Medicine CzMA
0 0 2 2 4
Czech Society of Cardiology 2 3 4 2 11
Czech Society of Nephrology 0 0 1 0 1
Czech Society for the Study of 
Obesity
1 0 1 0 2
Czech Society for Oncology 0 0 0 1 1
Czech Paediatric Society 1 0 0 0 1
Czech Pneumological and 
Phthiseological Society
3 4 11 0 18
Czech Society for 
Atherosclerosis
0 0 1 1 2
Czech Society for Hypertension 0 0 1 0 1
Czech Society for Thrombosis 
and Haemostasis
6 0 0 0 6
Society of Occupational 
Medicine
1 0 0 0 1
Czech Society for Metabolic 
Bone Diseases
0 1 0 0 1
Czech Society of 2 0 1 0 3
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Gastroenterology
Czech Society of Haematology 3 0 0 0 3
Czech Society of Hepatology 1 0 0 0 1
Czech Menopause and 
Andropause Society
0 0 1 0 1
Czech Society of General 
Practice
3 4 6 5 18
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DISCUSSION
Despite the clinical significance of smoking, few medical professional societies in the 
CR adequately addressed tobacco dependence and treatment in their CPG documents. 
One quarter of the selected CPG documents did not include any mention of smoking. 
Only 16% of CPG named smoking as a risk factor for cardiovascular and respiratory 
diseases, cancer, and related comorbidities.
Forty two percent of CPG documents contained a recommendation to quit smoking, 
most often using the phrase “smoking ban”. Some documents used terms such as 
“minimize” or “restrict smoking”. It would be appropriate to replace these terms with 
a clear recommendation for patients to stop smoking. This means zero exposure to 
tobacco smoke, including secondhand smoke. The ultimate goal for patients is 
smoking cessation, not reduction because there is no safe level of tobacco exposure 
(U.S. Department of Health and Human Services, 2014). If we recommend that 
tobacco-dependent patients reduce the number of cigarettes without medication, the 
patient smokes the reduced number of cigarettes more intensively. This is known as 
compensatory smoking as it allows the patient to obtain the required dose of nicotine 
with fewer cigarettes and reduces withdrawal symptoms (Shahab, 2012; NICE, 2013).
The majority (80%) of smokers are physically addicted to nicotine and cannot stop 
smoking without help (Balfour, et al., 2004; Stead et al., 2008). It is therefore 
important to proactively offer smokers treatment and information on where they can 
seek help, when they are ready to quit. In this study, we focused on CPG because they 
are a key component of evidence-based medicine (Brownson et al., 2011). CPG from 
the Czech Society of Cardiology state that “no drug can reduce cardiovascular 
mortality, by 25‒50%, as effectively as smoking cessation” (Widimský, et al., 2002). 
Only 14% of the selected CPG documents included the points of a brief intervention, 
a more detailed section on tobacco dependence treatment or a link to the Guidelines 
for Tobacco Dependence Treatment. CPG from the UK’s National Institute for Health 
and Care Excellence (NICE) may be a good example of how tobacco treatment 
guidelines can be incorporated into the Czech CPG. The NICE guidelines state that 
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one of the points of care for the patient with a concrete diagnosis of nicotine 
dependence is to offer advice to quit smoking, and provides links to the guidelines for 
brief interventions and Smoking Cessation Services in the UK  (NICE, 2009; 2006; 
2008).
Limitations of this study may include the parameters of CPG documents selected, the 
changing number of medical professional societies, the availability of CPG freely 
online, as well as the number of CPG documents published by each society. We chose 
only CPG documents related to clinical practice of cardiovascular and respiratory 
diseases, and cancer. However, all physicians should intervene with smokers 
regardless of their area of specialization. A brief intervention for tobacco dependence 
is simple, quick (3‒5 minutes), and effective (Fiore et al., 2008). It would be well 
justified to recommend that a brief intervention should be conducted with all smokers. 
Tobacco dependence treatment guidelines should be included in all CPG, including 
those that were not included in this survey.
The presence of a short description of the brief intervention or reference to the 
guidelines for tobacco dependence treatment in CPG documents may help remind 
physicians of the importance of routinely providing a brief intervention to patients 
who smoke. More recent research has shown a shorter form of the 5 A’s model to be 
effective for busier clinics or providers. The Mayo Clinic, Rochester, MN, USA uses 
the 2 A’s (Ask, Advice) and R (Refer) to the Nicotine Dependence Centre (Hurt et al., 
2009; Schroeder 2005; Campbell et al., 2006). The treatment in specialized Centres 
for Tobacco-Dependent (CTD) (Society for Tobacco Dependence Treatment, 2014) in 
the CRis carried out according to current evidence based guidelines (Fiore et al., 
2008; Králíková et al., 2015). Since 2013, the Czech Society for Tobacco Dependence 
Treatment has begun to advocate that professional societies include more detailed 




CPG documents from selected medical professional societies in the CR did not 
adequately address the importance of smoking cessation. Smoking cessation should 
not be viewed as a mere lifestyle change, but rather imperative to good health and a 
necessary part of treatment for many diseases. CPG are an important source of 
evidence-based information for clinicians. CPG should provide up to date information 
on tobacco dependence, treatment and highlight the importance of using brief 
intervention with patients who smoke at each clinical contact.
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8.0 CONCLUSIONS
Tobacco related chronic diseases are an enormous and growing burden on the Czech 
health care system. Lessons learned and experiences of global TC leaders, such as 
Canada, may provide the Czech Republic with a roadmap to help guide decisions 
makers in identify policy best buys moving forward. Despite the high social and 
economic costs of tobacco use, at a systems level few Czech organizations are 
involved in chronic disease prevention activities that address tobacco use. Among 
organizations involved, many are under resourced, lack core chronic disease 
prevention skills and face many barriers to moving the tobacco control agenda 
forward. 
Brief intervention for treatment of tobacco dependence is still not part of routine care 
and treatment is not accessible for many tobacco users. Despite strong evidence that 
shows that nicotine replacement therapy increases cessation rates, pharmacotherapy is 
still not covered by health insurance plans in the Czech Republic. 
Many tobacco users suffer from chronic health conditions and continue to smoke 
despite knowing that cessation would have many long-term health benefits. This 
speaks to the level of nicotine dependence, rather than a lack of motivation. Screening 
protocol and referral procedures to help patients who may benefit from treatment of 
nicotine dependence are inconsistent or unreliable. This represents an important gap 
in the Czech health care system.
Further to this, clinical practice guidelines do not adequately address tobacco use, or 
offer evidence based treatment guidelines that would help guide practitioners in how 
to help patients who smoke. This represents a major gap in knowledge translation. 
Our findings provide empirical evidence that there are major gaps relating to 
treatment of tobacco dependence, as well as tobacco control more generally within the 
Czech Republic.  In order to move the tobacco control agenda forward there is a need 
to build a comprehensive and sustainable national strategy for multi-sectoral tobacco 
control programs and policies within the Czech Republic. 
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